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2Chapter 1
INTRODUCTION
31.1  Peptidomimetics
The advent of genomics, molecular biology and structural biology with high-throughput X-
ray crystallography and high field NMR, provided many opportunities for structural and
functional analysis of a wide array of biologically active peptides. The critical roles that
proteins play at all levels of biological regulation have opened a large potential for
therapeutic intervention with recombinant proteins. However, the use of peptides as
therapeutics is limited due to several factors, including poor bioavailability, rapid
proteolytic degradation and clearance, low scale up feasibility, weak selectivity and high
production cost.
Besides all these drawbacks, biomedical research is constantly oriented towards the
development of new therapeutics based on peptides and proteins, by introducing specific
modifications and maintaining the features responsible for biological activity.1
A peptidomimetic compound may be defined as a substance having a secondary structure
and other structural features similar to native peptide such that it binds to enzymes or
receptors with higher affinity than the starting peptide.
Peptidomimetics are much more selective and efficient than native peptides, thus resulting
in less side effects, greater oral bioavailability and a prolonged biological activity due to
lowered enzymatic degradation.2
The knowledge of the structure-activity relationship or the three dimensional structure of
bioactive conformations is a promising route to rapidly achieve the best compound without
generating an enormous number of compounds with poor biological activity.
Several peptidomimetics are reported in literature, a clear example is the thyrotropin-
releasing hormone (TRH) mimetic, based on a cyclohexane scaffold. The TRH is an
interesting tripeptide for its potential to treat cognitive disorders, including those associated
with Alzheimer’s disease. The mimetic consists in a 1,3,5-cis-trisubstituted cyclohexane
framework which replaces the peptide backbone and bears all the pharmacophoric groups
with the correct orientation for activity. Moreover, by conferring additional rigidity to the
                                                
1 a) Giannis, A.; Kolter, T. Angew. Chem. Int. Ed. Engl. 1993, 32, 1244-1267; b) Gante, J. Angew. Chem. Int.
Ed. Engl. 1994, 33, 1699-1720; c) Adessi, C.; Soto, C. Curr. Med. Chem. 2002, 9, 963-978
2 Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bös, M.; Cook, C. M.; Fry, D. C.; Graves, B. J.; Hatada, M.; Hill,
D. E.; Kahn, M.; Madison, V. S.; Rusiecki, V. K.; Sarabu, R.; Sepinwall, J.; Vincent, G. P.; Voss, M. E. J.
Med. Chem. 1993, 36, 3039-3049
4system, cyclohexane determines an increase of biological activity, though side chains
rotation is still allowed.2 (Fig. 1)
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Figure 1. Rational approach towards the development of a peptidomimetic of TRH
51.2  Bicycle molecular scaffolds (BTAa): a class of conformationally
constrained dipeptide isosteres
In 1999, our research group reported on a new class of bicycle compounds based on 6,8-
dioxa-3-azabicyclo[3.2.1]octane structure. Such scaffolds, named BTAa (Bicycles from
Tartaric acid and Amino acids), derived from the combination of tartaric acids and amino
acid derivatives.3 (Fig. 2)
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Figure 2. BTAa structure
The main feature displayed by these molecules is the possibility of the rigid skeleton to act
as a dipeptide isostere, as every functional group present on the native peptide is found at
the isosteric position in the scaffold. (Fig. 3)
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Figure 3. BTAa scaffold acting as dipeptide isostere
Moreover, they satisfy all the requirements needed for the development of a
peptidomimetic: their synthesis includes only few steps starting from commercially
available enantiopure precursors and a stereochemistry control can be accomplished in
each step of the synthesis; a high number of positions can be functionalised leading to
molecular diversity; finally, all functional groups are well-suited for Solid Phase Peptide
Synthesis, and the presence of low number of energetically permitted conformations is
consistent with the ability to induce constraints in a peptide framework.
First generation of BTAa compounds was accomplished according to the retrosynthetic
scheme as in Figure 4. The combination of tartaric acid and α-amino aldehyde derivatives
                                                
3 a) Guarna, A.; Guidi, A.; Machetti, F.; Menchi, G.; Occhiato, E. G.; Scarpi, D.; Sisi, S.; Trabocchi, A. J.
Org. Chem. 1999, 1, 1407-1409; b) Trabocchi, A.; Menchi, G.; Guarna, F.; Machetti, F.; Scarpi, D.; Guarna,
A. Synlett 2006, 331-353
6generates a scaffold with an amide group, which can be successively transformed into a
bicycle amino ester or amino acid by selective reduction of the lactam moiety.
In particular, a given configuration of the stereogenic centre of amino aldehyde is obtained
from the corresponding amino acid, and the choice of tartaric acid isomer, either D-, L- or
meso, contributes to the overall stereochemical set of BTAa compounds.
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Figure 4. Retrosynthesis of BTAa from α-amino aldehyde and tartaric acid derivative
Further experiments allowed to expand the choice of building blocks from the chiral pool
in order to broaden the class of BTAa scaffolds. Sugar derivatives and amino ketones were
successfully applied to give access to compounds with added diversity relatively to
stereochemistry and functional group variety.3b
As dipeptide isosteres, BTAas are compounds with potential biological activity and their
use as central core of pharmaceutical targets is convenient as a high number of positions
can be functionalised leading to  several molecular libraries.
The limited flexibility of the skeleton may correctly direct the pharmacophore side chains
and it may be useful also for computational analysis. In addition, fair solubility and low
molecular weight validate these scaffolds as potential drug candidates.
7 1.3  Proteases
Proteases are enzymes that catalyse the breakdown of proteins by hydrolysis of peptide
bonds. Approximately 2% of the genes in most organisms are proteases, second in number
only to transcription factors, and they are involved in almost every physiological process
even using different catalytic mechanisms for substrate hydrolysis. 4
The main function of proteases was long considered to be protein degradation relevant to
food digestion and intracellular protein turnover, however, it was discovered that precise
cleavage of proteins by proteases leads to a very subtle means of regulation.
Therefore, proteases are involved in the control of a large number of key physiological
processes such as cell-cycle progression, cell proliferation and cell death, DNA replication,
tissue remodelling, haemostasis, wound healing and the immune response. This leads to
understand why proteases are such important drug targets, and the efforts to validate them
as targets and identify or design efficient drugs against them.
Proteases can be subdivided into two major groups: exopeptidases and endopeptidases. The
former progressively hydrolyses peptides or proteins starting from the amino acids at their
termini, producing a mixture of amino acids. The latter hydrolyses an internal peptide bond
resulting in the formation of two or more peptides as reaction products. They usually
recognize specific sequences or amino acids.
Most endopeptidases are classically subdivided into 4 classes, depending on the chemical
groups taking part in the hydrolytic reaction: 1) serine proteases, 2) cysteine proteases, 3)
metalloproteases and 4) aspartic proteases.
The first two classes are characterized by a so called “catalytic triad”, consisting of serine,
histidine and aspartate in serine proteases and of cysteine, histidine and aspartate in
cysteine proteases. Metalloproteases are characterized by the direct involvement of a metal
ion, usually zinc, in the catalytic process and they do not form covalent enzyme-substrate
intermediates. Aspartic proteases are characterized by having in the catalytic site two
aspartate residues linked to a water molecule by hydrogen bonds.
The research activity developed during my PhD in Structural Biology is focussed on two
main branches related to the research of new potential selective inhibitors of
                                                
4 a) Puente, X.S.; Sanchez, L. M.; Overall, C. M.; Lopez-Otin, C.; Nature Rev. Genet. 2003, 4, 544-558; b)
Boris Turk Nature rev. Drug Discovery 2006, 5, 785-799
8Metalloelastase (MMP-12), belonging to the Matrix Metalloproteases family, and of
Candida Albicans Secreted Aspartyl Protease 2 (Sap2).
91.4  Matrix Metalloproteases
Matrix metalloproteinases (MMPs) are a family of zinc dependent, calcium containing,
endopeptidases involved in extracellular matrix degradation and, consequently, they play a
crucial role in physiological processes such as tissue remodelling and healing of wounds.5
As the upregulation of MMPs is involved in many inflammatory, malignant and
degenerative diseases,6 attempts to design and develop inhibitors that may modulate their
regulation have become of great interest.7
Although the number and nature of subunits can differ, MMP catalytic domain structures
are highly similar, with a sequence identity of 50%-60%. The catalytic domain of each
enzyme possesses an overall spherical topology characterized by a twisted five-stranded β-
sheet, containing four parallel and one antiparallel strand, and three long α-helices. The
conserved active-site sequence motif HEXXHXXGXXH coordinates the catalytic zinc(II)
ion and contains a glutamic acid residue which facilitates the catalysis.7a
Two zinc atoms, one playing a catalytic and the other a structural role, are present in the
MMP catalytic domain. The catalytic zinc ion coordinates with the three histidine residues
contained within the sequence of the catalytic domain.
The enzyme latency is given by a thiol group of the cysteine residue within the propeptide
which coordinates to the catalytic zinc atom. This interaction must be broken by
proteolytic cleavage of the amino-terminal domain, or by conformational modification,
before the metalloproteinase can degrade matrix proteins.
Once activated, MMPs are subject to inhibition by endogenous proteinase inhibitors such
as the family of Tissue Inhibitors of MetalloProteinases, TIMPs. These negative regulatory
controls are clearly important for a family of enzymes with such destructive potential.
However, it appears that these controls do not always operate as they should, leading to a
wrong expression of MMP activity which constitutes part of the pathogenic mechanism in
several diseases.
                                                
5 Visse, R.; Nagase, H. Circ. Res. 2003, 92, 827-839
6 Mandal, M.; Mandal, A.; Das, S.; Chakraborti, T.; Chakraborti, S. Mol. Cell. Biochem. 2003, 252, 305-329
7 a) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Chem. Rev. 1999, 99, 2735-2776; b) Skiles, J. W.;
Gonnella, N. C.; Jeng, A. Y. Curr. Med.Chem. 2004, 11, 2911-2977; c) Fisher, J. F.; Mobashery, S. Cancer
Metastasis Rev. 2006, 25, 115-136
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Figure 5. MMP proteolysis reaction mechanism
The reaction mechanism for proteolysis by MMPs is depicted in Figure 5. It is proposed
that the scissile amide carbonyl coordinates to the active-site zinc(II) ion. This carbonyl is
attacked by a water molecule that is both hydrogen bonded to a conserved glutamic acid
and coordinated to the zinc ion.
During the proteolytic process the positively charged zinc(II) ion helps to stabilize negative
charge at the oxygen of the scissile amide and a conserved alanine residue helps to
stabilize positive charge at the nitrogen of the scissile amide.7a
From X-ray crystallographic analysis and homology modelling the MMPs may be
classified as falling into two broad structural classes dependent on the depth of the S1'
pocket. This "selectivity pocket" is relatively deep for the majority of the enzymes (e.g.,
MMP-2, MMP-8, MMP-9, MMP-12, MMP-13, etc.), but for certain enzymes (e.g., MMP-
1, MMP-7, and MMP-11) it is partially or completely occluded due to an increase in the
size of the side chain of the amino acids that form the pocket.
On the contrary, the other pockets of the binding site,  even if they are not similar, show
limited opportunities for a tight and selective binding, because they are either shallow or
solvent exposed.
Over the last twenty years, many efforts were oriented towards the search of potent MMP
inhibitors (MMPIs) and the most drug candidates developed to date achieves a tight
binding via extensive van der Waals contacts within the largely hydrophobic interior of the
S1’ pocket and by strong electrostatic interactions with the catalytic zinc ion.
Although the big effort of the scientific committee for the search of potent MMPIs,
unfortunately, clinical trials on drug candidates did not show significant benefits and to
date, no inhibitor of an MMP catalytic domain has become a drug.
11
Such insuccess may be due to the fact that the inhibitor concentration reached in vivo is
insufficient to inhibit target enzymes in the tissue or that non-target enzymes are inhibited.5
Since the first attempts to MMP inhibition, hydroxamic acid was the preferred zinc-
chelating group, even if some authors report that it is fast metabolised in vivo8 and it
contributes to increase toxicity due to its low metal binding selectivity.9
Batimastat, a peptidomimetic hydroxamic inhibitor is an early example of MMPIs, which
was extensively tested in preclinical studies. While being a potent inhibitor of MMPs with
broad specificity, it is relatively insoluble. Modification of Batimastat led to the synthesis
of an orally bioavailable derivative with similar inhibitory features, Marimastat, that was
more suitable for clinical studies. While it was not evident in preclinical studies, both of
these inhibitors when tested in the clinic promoted musculoskeletal pain as side effect.10
The problem of selectivity is further complicated  by the presence of ADAM (A
Disintegrin And Metalloproteinase) family. These membrane bound enzymes act as
sheddases, liberating membrane bound cytokines, cell surface receptors, and growth
factors as physiologically active soluble proteins. The catalytic site of ADAM enzymes
also manifest the MMP signature sequence HEXXHXXGXXH, and small molecules that
inhibit MMPs frequently also inhibit ADAM family members. It was also suggested that
musculoskeletal pain associated with broad-spectrum MMP inhibitors may be due to
simultaneous inhibition of ADAM proteins. This makes selectivity within and between the
families even more important.
Hydroxamate replacements such as thiols, phosphonates, thiadiazoles, thiadiazines,
barbituric acids, and hydantoins were investigated. Most of them are affected by weaker
affinity, reduced absorption rates, or toxicity; as a result, the search for improved, novel
zinc binding groups is a continuous challenge.7c, 11
                                                
8 a) Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetz, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.;
Brooks, D. W.; Carter, G. W. J. Med. Chem. 1987, 30, 2121-2126; b) Michaelides, M. R.; Dellaria, J. F.;
Gong, J.; Holms, J. H.; Bouska, J. J.; Stacey, J.; Wada, C. K.; Heyman, H. R.; Curtin, M. L.; Guo, Y.;
Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.; Morgan, D. W.; Davidsen, S.
K. Bioorg. Med. Chem. Lett. 2001, 11, 1553-1556
9 Breuer, E.; Frant, J.; Reich, R. Expert Opin. Ther. Patents 2005, 15, 253-269
10 Pavlaki, M.; Zucker, S. Cancer Metastasis Rev. 2003, 22, 177-203
11 a) Puerta, D. T.; Lewis, J. A.; Cohen, S. M. J. Am. Chem. Soc. 2004, 126, 8388-8389; b) Wasserman, Z. R.
Chem. Biol. 2005, 12, 143-144
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The inhibitors designed up to date usually bind the active site on the catalytic domain
providing nanomolar dissociation constants.7ab, 12 However, several inhibitors exhibit a
poor selectivity as a consequence of the high structural similarity among the members of
the MMP family.13 Even if the low specificity does not prevent the use in vivo, it raises a
lot of side effects and it also limits the dose that may be daily administered.10, 14 As a
consequence, the search of new potent and selective MMP inhibitors able to get through
the clinical trials, still represents an important pharmaceutical target.
                                                
12 Fisher, J. F.; Mobashery, S. Cancer Metastasis Rev. 2006, 25, 115-136
13 Lukacova, V.; Zhang, Y. F.; Mackov, M.; Baricic, P.; Raha, S.; Calvo, J. A.; Balaz, S. J. Biol. Chem. 2004,
279, 14194-14200
14 Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Science 2002, 295, 2387-2392
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1.5  Aspartyl Proteases
Aspartyl proteases are a family of endonucleases which is widely distributed in many
organisms and tissues with different physiological and functional properties.
Aspartic proteinases contain two aspartyl residues at the active site, one protonated and the
other not, which work together as general acid-base catalysis. A water molecule bound
between the two aspartates is believed to be the nucleophile for the amide bond hydrolysis
and it is activated by the deprotonated catalytic aspartic acid residue. The nucleophilic
attack by the water’s oxygen to the carbonyl generates a tetrahedral intermediate whose
breakdown results in the formation of amide hydrolysis products.15
To catalyse peptide hydrolysis, the two aspartic residues must be close enough in the
tertiary structure of the molecule. They are quite far from each other in the primary
structure of most aspartic proteases and the bilobed three dimensional folding allows them
to be in sufficient vicinity in the catalytic site.
Most of the aspartic proteinases belong to the pepsin family, including digestive enzymes
such as pepsin and chimotripsin as well as lysosomal cathepsins D and processing enzymes
such as renin and certain fungal proteases (the Candida Albicans saps, penicillopepsin etc).
A second family comprises viral proteinases such as the HIV also called retropepsin.
The active site of aspartic proteases does not in general contain groups that are sufficiently
nucleophilic to be chemically modified by a selective irreversible inhibitor. Thus, most of
the aspartic protease inhibitors developed to date binds to their target enzyme through non
covalent interactions. These compounds are therefore reversible inhibitors and an effective
inhibition results when the enzyme shows higher affinity for the inhibitor than for its
natural substrate.16
It was proposed that stable structures which resemble the transition state of the enzyme
catalysed reaction should bind the enzyme more tightly than the substrate. As a
consequence, a very successful approach for the design of efficient aspartyl protease
inhibitors is based on the incorporation of a transition state isostere into a peptidomimetic
structure.
                                                
15 a) Kostka, V., Ed. Aspartic Proteinases and Their Inhibitors Walter de Gruyter: Berlin, 1985; b)
Chitpinityol, C.; Crabbe, M. J. C. Food Chem. 1998, 61, 395-418
16 Tacconelli, E.; Savarino, A.; De Bernardis, F.; Cauda, R.; Cassone, A. Curr. Med. Chem. 2004, 4, 49-59
14
Candida Albicans is an opportunistic fungal pathogen that causes severe systemic
infections especially in immunodeficient individuals.
There is a limited number of antifungal agents available17 and the need for new drugs
against C. Albicans is escalating due to both the widespread occurrence of mucosal
infections caused by Candida, and the development of resistance against available drugs.18
Although the ability to cause disease is likely a complex process involving multiple
interactions between Candida and the host, Secreted Aspartyl Proteases (Saps) activity
appears to be the virulence factor and therefore offers a potential target for drug
intervention in infections.
The Candida strains express at least eight distinct genes (Sap 1-8) during the course of the
same disease but to different stages of infection, indicating that the different Saps have
different functions;19 Sap2 is one of the most expressed enzymes implicated in host
invasion and its crystal structure is known and it is of major utility for structure designed
inhibitors.20
                                                
17 Rogers, T. R. Curr. Opin. Crit. Care 2001, 7, 238-241
18 White, T. C.; Marr, K. A.; Bowden, R. A. Clin. Microbiol. Rev. 1998, 11, 382-402
19 Schaller, M.; Schackert, C.; Korting, H. C.; Januschke, E.; Hube, B. J. Invest. Dermatol. 2000, 114, 712–
717
20 Cutfield, S. M.; Dodson, E. J.; Anderson, B. F.; Moody, P. C. E.; Marshall, C. J.; Sullivan, P. A.; Cutfield,
J. F. Structure, 1995, 3, 1261-1271
15
1.6  Aims of the research project
In this PhD thesis new aspects are described about the design and synthesis of new
molecular scaffolds having a suitable structure for acting as potential selective inhibitors of
Metalloelastase (MMP-12) or of Candida Albicans Sap2.
Moreover, since the continuous interest towards innovative hydroxamate bioisosteres and
the various potential applications of N-hydroxyurea derivatives in biological systems, a
further purpose of this study consists in the investigation on new synthetic procedures on
solid support which may allow the easily achievement of a large collection of different N-
hydroxyurea molecules.
Thus, it will be reported about:
- The design and synthesis of BTAa derivatives showing a fair inhibition potency
towards Metalloelastase and some selectivity for different MMPs, through a
combined use of in silico screening, experimental determination of binding affinity
by 15N-1H HSQC NMR experiments and X-ray structure analysis.
- The development of a new and efficient method for the synthesis of a novel proline
mimetic based on the 6,8-dioxa-3-azabicyclo[3.2.1]octane scaffold.
- The investigation towards a new Solid Phase Organic Synthesis method to convert
Fmoc-protected amino acids into O-protected N-hydroxyureas.
- The research of new potential inhibitors of Sap2, a major secreted aspartic
proteinase from Candida Albicans, through two different and parallel pathways
consisting in a random screening and in a rational drug design.
16
Chapter 2
RESULTS and DISCUSSIONS
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2.1  BTAa molecular scaffolds as potential inhibitors of Macrophage
Metalloelastase
Human macrophage metalloelastase (MMP-12) is a member of the MMP family which is
very active against a broad range of extra cellular matrix components including elastin,
fibronectin, laminin, entactin, proteoglycans and collagen IV.21, 22
Being able to degrade elastin, the major elastic fiber component providing resilience to
tissues, MMP-12 is involved in the progressive structural damage associated with
emphysema and other forms of chronic obstructive pulmonary disease (COPD).23
Although several drug candidates showing nanomolar dissociation constants are reported
in literature, the search of new potential inhibitors still represents an important
pharmaceutical target to reach better selectivity and avoid side effects.
The crystal structure analysis of the catalytic domain of human recombinant MMP-12
complexed with the broad spectrum inhibitor Batimastat (BB-94) reveals an overall fold
similar to that of other MMPs.24
However, the characteristic S1’ subsite is a continuous tube rather than a pocket, in which
the specific Thr215 replaces a valine residue, otherwise highly conserved in almost all
other MMPs, leading to a more polar interior of this subsite.
The availability of high-resolution structure of the MMP-12 catalytic domain24, 25 provided
the possibility to employ a structure-based approach to design and screen a virtual library
with the aim to find out new specific inhibitors for emphysema therapy.
We reasoned that potential MMP-12 inhibitors could be based on the versatile BTAa
scaffold. Indeed, the high degree of molecular diversifications together with a proper
spatial orientation of the pharmacophoric groups may be crucial for designing truly
specific inhibitors.
                                                
21 Belaaouaj, A.; Shipley, J. M.; Kobayashi, D. K.; Zimonjic, D. B.; Popescu, N.; Silverman, G. A.; Shapiro,
S. D. J. Biol. Chem. 1995, 270, 14568-14575
22 Mecham, R. P.; Broekelmann, T. J.; Fliszar, C. J.; Shapiro, S. D.; Welgus, H. G.; Senior, R. M. J. Biol.
Chem. 1997, 272, 18071-18076
23 Hautamaki, R. D.; Kobayashi, D. K.; Senior, R. M.; Shapiro, R. S. Science 1997, 277, 2002-2004
24 Lang, R.; Kocourek, A.; Braun, M.; Tschesche, H.; Huber, R.; Bode, W.; Maskos, K. J. Mol. Biol. 2001,
312, 731-742
25 Bertini, I.; Calderone, V.; Cosenza, M.; Fragai, M.; Lee, Y.-M.; Luchinat, C.; Mangani, S.; Terni, B.;
Turano, P. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5334-5339
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Firstly, in order to check if the scaffold could well accommodate in the MMP-12 catalytic
domain and to find the best orientation for the flanking units, we decorated BTAa
compounds with the most used pharmacophoric groups for MMP inhibition: the
hydroxamate as ZBG, and the biphenylic residue to fit in the S1’ pocket.26
Once demonstrated that the molecules provided by docking calculations fit in the catalytic
pocket of MMP-12, we started the long challenging route of chemical modification of the
scaffold to get not only an improved binding, but also better selectivity and
pharmacokinetic properties.
A biphenylic moiety and a hydroxamic (or carboxylic) acid were chosen as good
substituents to be introduced in different position of BTAa scaffolds and hundreds of
structures were so generated and tested in silico for their affinity to the catalytic domain of
MMP-12.
Even if the binding energy provided by docking programs does not reflect exactly the real
binding affinity, its value allows to score the docking results in order to identify a class of
potential ligands.27
Moreover, the experimental assessment of the affinity of few selected molecules outlined
by docking results gives the chance to correlate binding energies and binding constants
improving the prediction reliability.
The hits with the highest score were selected and, among them, compounds 1-4 were
synthesized due to their higher feasibility.28 In this class of molecules the scaffold supports
the biphenylic moiety in front of the ZBG.
The Autodock binding model predicted a deep insertion of the biphenyl group into the S1’
cavity though the coordination geometry of the ZBG appeared not to be optimized.
Dissociation constants (KD) of compounds 1–4 were calculated through 15N–1H HSQC
experiments.29 In addition, compounds 7–10, already present in our chemical library, were
                                                
26 Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.;
Steinman, D. H.; Carrera, G. M.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer,
R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. J. Am. Chem. Soc. 1997,
119, 5818-5827
27 Klebe, G.; Gräder, U.; Grünemberg, S.; Krämer, O.; Gohlke, O.; Understanding Receptor–Ligand
Interaction as a Prerequisite for Virtual Screening. In Virtual Screening for Bioactive Molecules, H. J.
Böhm, G. Schneider, Eds.; Wiley–WCH, Weinheim, Germany, 2000; pp 207-227
28 Mannino, C.; Nievo, M.; Machetti, F.; Papakyriakou, A.; Calderone, V.; Fragai, M.; Guarna, A. Bioorg.
Med. Chem. 2006, 14, 7392-7403
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submitted to the same experiments in order to compare the results and support the docking
model.
Moreover, the inhibitory activity (IC50) of compounds 1–4 was measured by enzymatic
assays.30
The values of KD and IC50 for all the tested compounds are reported in Table 1.
Table 1. Calculated MMP-12 binding affinity (KD) and inhibition potency (IC50).
N OO
R''
R
R'
O
Compound X R R’ R” MMP-12KD [c]
MMP-12
IC50 [d]
1 O p-PhBn H COOH ≥ 1mM 954 µM
2 H, H p-PhBn H COOH ≥  1mM 835 µM
3 O p-PhBn H CONHOH ≥500 µM 425 µM
4 H, H p-PhBn H CONHOH ≥500 µM 399 µM
5 H, H HONHCO H CONHp-PhBn 154 µM 149 µM
6 O HONHCOCH2 H CONHp-PhBn 114 µM -
7[a] O Bn H COOH ≥ 10mM -
8[a] H, H Bn H COOH ≥  10mM -
9[a] O Bn H CONHOH ≥ 10mM -
10[a] H,H p-PhBn COOH H not detec.[b] -
11 N
OEt
O
NH
O
HO
3.4 mM -
[a] Compounds previously described 5, 6, 31, 32; [b] not detectetable interaction found by NMR; [c] dissociation
constants measured through 15N-1H HSQC NMR experiments; [d] inhibition potency measured by
fluorescence enzymatic assays.
Since the identification of the amino acids involved in the binding may be crucial to prove
a direct interaction with the catalytic site and, consequently, for the optimisation of the
                                                                                                                                                   
29 Mitton-Fry, R. M.; Anderson, E. M.; Hughes, T. R.; Lundblad, V.; Wuttke, D. S. Science 2002, 296, 145-
147
30 Knight, C. G.; Willenbrock, F.; Murphy, G. FEBS Lett. 1992, 296, 263–266
31 Guarna, A.; Bucelli, I.; Machetti, F.; Menchi, G.; Occhiato, E. G.; Scarpi, D.; Trabocchi, A. Tetrahedron
2002, 58, 9865-9870
32 Trabocchi, A.; Cini, N.; Menchi, G.; Guarna, A. Tetrahedron Lett. 2003, 44, 3489-3492
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process, NMR-based strategies were also used to localize the binding site on the target.33
The identification of the binding site was easily performed analysing the protein resonance
chemical shifts in 1H–15N HSQC spectra, recorded either in presence or in absence of the
ligand.34
The pattern of the shifts was similar for all ligands. Several residues forming the S1’
cavity, one or more zinc binding histidines and the neighbouring amino acids are strongly
influenced by the presence of this class of molecules. As example, a ribbon representation
of MMP-12 is shown in Figure 6. The NHs showing significant chemical shift perturbation
upon the addition of compound 4 are highlighted. The affected amino acids nicely define
the ligand binding site that is the same for all the designed compounds in agreement with
the docking results. Only few differences were found among the members of this class. In
particular, the NH cross-peak of His218 was only weakly shifted by lactams 1 and 3 with
respect to compound 4.
Figure 6. A) Surface model of the MMP-12 showing the catalytic zinc and the S1’ pocket; B) Residues of the
MMP-12 affected by chemical shifts perturbation upon the addition of 4.
The analysis of the results summarized in Table 1 suggests that the bicyclic skeleton of
BTAa should be compatible with the metalloelastase catalytic domain, but the activity is
strongly modulated by the type and position of substituents.
                                                
33 Pellecchia, M.; Becattini, B.; Crowell, K. J.; Fattorusso, R.; Forino, M.; Fragai, M.; Jung, D.; Mustelin, T.;
Tautz, L. Expert Opin. Ther. Targets 2004, 6, 597-611
34 Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Science 1996, 274, 1531-1534
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Since the experimental results showed first evidence of a fair inhibitory activity, we
decided to focus our efforts on the design of new derivatives with improved affinity. A
deeper penetration in the S1’ cavity was possible moving the biphenyl group quite far from
the scaffold. Due to the high reactivity of the BTAa methyl ester, it was synthetically very
easy to introduce the biphenylic moiety in 7 through an amide bond. As a consequence, the
best anchoring point for the ZBG resulted in the N-3 giving rise to the N-hydroxyurea 5.
The use of the hydroxyurea group as metal chelator in MMP inhibitors has been previously
reported35 and recently validated by a X-ray structure.36
In order to determine the affinity of the N-hydroxyurea moiety with the MMP-12 catalytic
zinc ion, the model compound 11 was tested in silico and synthesized. Since the metal
binding capability of the N-hydroxyurea was confirmed, the new scaffold 5 was
synthesized.
The 1H–15N HSQC spectra for 5 showed a pattern of shifts similar to compounds 1–4
indicating for all these molecules the same binding site (Fig. 7). A different effect on the
zinc binding histidine with respect to the N-hydroxyurea prototype is probably present
since the shift perturbation involved mainly His222 instead of His218. The fit of ∆δ as a
function of the ligand concentration provided a KD of 154 µM, in good agreement with the
IC50 value of 149 µM obtained by the enzymatic assay.
                                                
35 Michaelides, M. R.; Dellaria, J. F.; Gong, J.; Holms, J. H.; Bouska, J. J.; Stacey, J.; Wada, C. K.; Heyman,
H. R.; Curtin, M. L.; Guo, Y.; Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.;
Morgan, D. W.; Davidsen, S. K. Bioorg. Med. Chem. Lett. 2001, 11, 1553-1556
36 Campestre, C.; Agamennone, M.; Tortorella, P.; Prezioso, S.; Biasone, A.; Gavazzo, E.; Pochetti, G.;
Mazza, F.; Hiller, O.; Tschesche, H.; Consalvi, V.; Gallina, C. Bioorg. Med. Chem. Lett. 2006, 16, 20-24
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Figure 7. A) 1H-15N HSQC spectrum of MMP-12 catalytic domain in absence (blue) and in presence (red) of
compound 5 (500 µM); B) Expansion of 1H-15N HSQC spectrum showing the shift of the His222 backbone
NH upon the addition of increasing concentration of compound 5.
To probe the selectivity towards MMP-12, N-hydroxyurea 5 was also tested by
fluorescence enzymatic experiments for the inhibition of collagenases (MMP-1, MMP-8,
MMP-13), matrilysin 1 (MMP-7) and stromelysin 2 (MMP-10) and the corresponding data
are summarized in Table 2.
Table 2. MMP enzyme inhibition potency of compound 5 measured by enzymatic assay
Compound IC50 (µM)
MMP-1 MMP-7 MMP-8 MMP-10 MMP-12 MMP-13
5 1180 1510 513 865 149 778
Compound 5 is a fairly selective MMP-12 inhibitor since it possesses limited activity
against the other MMPs especially the MMP-1 and MMP-7. These two enzymes differ
from other MMP family members since they have a relatively small S1’ pocket which
presumably cannot accommodate the large biaryl substituent.
A lack of activity with respect to MMP-1 is considered to be an important factor in
reducing some of the side effects found in drug candidates. Several MMP inhibitors, in
fact, showed a severe musculoskeletal syndrome as side effect, which seems to be linked to
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an impairment of normal tissue remodelling governed either by the MMP-1 or by
sheddases.
Although compound 5 exhibits an improved affinity towards MMP-12, nevertheless the
micromolar value of KD demonstrates that all the planned interactions are not optimized.
The X-ray structure of the MMP-12–5 complex (PDB code: 2HU6) provided a direct
inspection on ligand–protein interactions (Fig. 8).
Figure 8. Crystal structure of MMP-12-5 adduct, the zinc ion is coordinated by AHA
As correctly predicted by the NMR studies the molecule binds the metalloelastase at the
catalytic site, fitting the biaryl moiety into the S1’ pocket. The electron density of the
inhibitor is well defined because it is held in place by two hydrogen bonds with Pro238 and
Leu181 of the enzyme backbone, as clearly shown in Figure 9. However, the contribution
of the hydroxyurea to the binding is absolutely negligible since it points towards the
exterior of the active site and does not interact with the catalytic zinc ion. Noteworthy, the
zinc ion is coordinated by the weak inhibitor acetohydroxamic acid (AHA) present, as
stabilizer, in the crystallization buffer. This would suggest that the lack of interaction
between the hydroxyurea and the catalytic zinc, evidenced in the crystal structure, is due to
the competition with the high concentration of AHA.
24
Figure 9. Crystal structure of MMP-12-5 adduct, particular showing the two hydrogen bonds with Pro238
and Leu181 of the enzyme backbone.
In order to investigate this point, an energy minimization of the ligand was performed after
removing AHA from the PDB and blocking the biaryl group in the crystal structure
conformation. The AMBER-8 minimized model indicates that the hydroxyurea function
could coordinate the zinc ion, even if the hydrogen bond interactions with the zinc binding
site are not well defined as in the case of AHA (Fig. 10).
Figure 10. AMBER-8 minimized model of MMP-12-5 adduct.
As these data suggested that the anchoring point and/or the length of the ZBG are not
optimized, a more flexible  hydroxamic acid derivative (6) was obtained by inserting a
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methylene group between the ZBG and the scaffold with the aim to promote the binding
with the catalytic zinc ion (Scheme 1).
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Scheme 1. Reagents and conditions: (i) NEt3, MeOH, H2, Pd/C, r.t. o/n (59%); (ii) DCM, r.t. o/n; (iii) SOCl2,
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The synthesis of compound 6 was carried out following a procedure previously reported
for similar compounds and it is briefly reported below.37
Reductive alkylation of glycine methylester with dimethoxy-acetaldehyde (13) afforded
the secondary amine 14 which was subsequently converted into the amide 16 through a
coupling reaction with  tartaric acid derivative 1538. Treatment of crude 16 with thionyl
chloride in MeOH afforded cyclic acetal 17 which was further submitted to the acid-
catalysed cyclisation to yield 18 in 17% yield over the three steps.
Thanks to the peculiar reactivity of the methyl ester in 7, amide 19 was easily synthesized
in good yield  by mixing the scaffold with a small excess of p-phenyl-benzyl amine in
DCM at 40°C.
Basic hydrolysis of the methyl ester in 2 followed by a coupling reaction with O-benzyl
hydroxylamine afforded the protected hydroxamic acid 20. Mild hydrogenolytic cleavage
of the protecting group over 10% Pd/C yielded the title compound 6.
                                                
37 Guarna, A.; Guidi, A.; Machetti, F.; Menchi, G.; Occhiato, E. G.; Scarpi, D.; Sisi, S.; Trabocchi, A. J. Org.
Chem. 1999, 1, 1407-1409
38 Lucas, H. J.; Baumgarten, W. J. Am. Chem. Soc. 1941, 63, 1653-1657
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The 1H-15N HSQC spectra for 6 provided a KD of 114 µM which shows a weak
improvement in the activity even if the main binding contribution is still determined by the
insertion of the biphenyl moiety in the S1’ cavity.
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2.2  Synthesis of a bicyclic proline analogue from L-Ascorbic Acid
Peptides and proteins are essential elements of organisms. While proteins have biocatalytic
functions and are important components of tissues, peptides influence a multitude of
physiological processes as hormones, neurotransmitters and neuromodulators.
Since bioactive peptides play an important role in the appearance and maintenance of
various diseases, agents that could imitate or block their biological functions (agonist or
antagonist, respectively) were considered as aid for the investigation on therapeutics.
Bioactive peptides, due to their pharmacological properties, can be employed as drugs in
only a few cases. Therefore, peptidomimetics were developed with the aim to substitute
peptides in their interactions with receptors; indeed, in comparison with native peptides,
they show higher metabolic stability, better bioavailability and longer duration of action.
The need to replace natural amino acids in peptides with non-proteinogenic counterparts in
order to obtain drug-like target molecules stimulated a great deal of biomedical research.39
In this respect, the field of amino acids gained large relevance in recent years, particularly
with the emergence of unnatural analogues as components of molecules with therapeutic
potential.40
Of particular interest was the research of mimetics of the only cyclic proteinogenic α-
amino acid, proline, because it plays a critical role in protein folding and refolding.
As proline can exhibit cis-trans rotamerization around the amide bond, Xaa-Pro peptide
bond has approximately the same energy in both cis and trans conformer, unlike other
peptide amide bonds which adopt predominantly more stable trans conformations.
As a consequence, proline participates in nucleation of turns as well as in breaking of
helices in proteins, and exerts a significant influence upon a number of biologically
important processes.
Among the various approaches for mimicking peptide structures,41 numerous mimetics and
analogues of proline were developed  with the aim to gain more insight into the modulation
                                                
39 a) Giannis, A.; Kolter, T. Angew. Chem. Int. Ed. Engl. 1993, 32, 1244-1267; b) Gante, J. Angew. Chem.
Int. Ed. Engl. 1994, 33, 1699-1720; c) Olson, G.L.; Bolin, D.R.; Bonner, M.P.; B6s, M.; Cook, C.M.; Fry,
D.C.; Graves, B.J.; Hatada, M.; Hill, D.E.; Kahn, M.; Madison, V.S.; Rusiecki, V.K.; Sarabu, R.; Sepinwall,
J.; Vincent, G.P.; Voss, M.E. J. Med. Chem. 1993, 36, 3039.
40 a) Sardina, F.J.; Rapoport, H. Chem. Rev. 1996, 96, 1825; b) Ohfune, Y. Acc. Chem. Res.1992, 25, 360.
41 Hanessian, S.; McNaughton-Smith, G.; Lombart, H. G.; Lubell, W. D. Tetrahedron 1997, 53, 12789-12854
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of the cis/trans isomerism of acyl-proline bonds42 and to produce proline-like reverse turn
inducers;43 moreover, they were applied as central core of several pharmacologically active
small-molecules.44
Since the development of the first examples of 6,8-dioxa-3-azabicyclo[3.2.1]octane-based
scaffolds (BTAa, Fig. 11), various substituents were introduced at positions 3, 4, 5, and
7,45 whereas position 2 remained largely unexplored, occupied only by carbonyl,
tiocarbonyl, or methylene groups.
During the last years,  our research group explored the possibility of moving the carboxylic
group from the canonical 7exo position in terms of stereochemical and positional shift.
This challenge required the development of new efficient synthetic strategies to obtain new
BTAa-based amino acids.
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Figure 11. General formula of BTAa scaffolds (top) and isomeric bicyclic amino acids A–E, with A, D and E
as proline mimetics
                                                
42 a) Wang, Q.; Tran Huu Dau, M.-E.; Sasaki, N. A.; Potier, P. Tetrahedron, 2001, 57, 6455-6462; b)
Demange, L.; Cluzeau, J.; Ménez, A.; Dugave, C. Tetrahedron Lett. 2001, 42, 651-653
43 a) Kym, K.; Germanas, J. P. J. Org. Chem. 1997, 62, 2847-2852; b) Zhang, W. J.; Berglund, A.; Kao, J. L.-
F.; Couty, J. P.; Gershengorn, M. C.; Marshall, G. R. J. Am. Chem. Soc. 2003, 125, 1221-1235
44 a) Cheng, M.; De B.; Almstead, N. G.; Pikul, S.; Dowty, M. E.; Dietsch, C. R.; Dunaway, C. M.; Gu, F.;
Hsieh, L. C.; Janusz, M. J.; Taiwo, Y. O.; Natchus, M. G. J. Med. Chem. 1999, 42, 5426-5436; b) Damour,
D.; Herman, F.; Labaudinière, R.; Pantel, G.; Vuilhorgne, M. ; Mignani, S. Tetrahedron 1999, 55, 10135-
10154 ; c) Dahlgren, A.; Braualt, J.; Kuaenström, I.; Nilsson, I.; Musil, D.; Samuelsson, B. Bioorg. Med.
Chem. 2002, 10, 1567-1580; d) Wang, X. J.; Hart, S. A.; Xu, B.; Mason, M. D.; Goodell, J. R.; Etzkorn, F. A.
J. Org. Chem. 2003, 68, 2343-2349
45 Trabocchi, A.; Menchi, G.; Guarna, F.; Machetti, F.; Scarpi, D.; Guarna, A. Synlett 2006, 331-353
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A complete change of the COOH position was firstly achieved using side chain of serine as
source of the carboxylic moiety. A new set of bicyclic compounds, named BGS, was then
synthesized. The shift of the carboxyl moiety from position 7 to 4 allowed the generation
of constrained unnatural α-amino acids showing structural features similar to proline.46
(Fig. 11, A)
Successively, a novel procedure to obtain a new scaffold with the carboxyl function in
position 5 allowed the generation of a β-amino acid isomeric to α-amino acids BGS and to
γ/δ-amino acid BTG compounds.47 (Fig. 11, C)
In order to complete the collection of amino acids that the BTAa scaffold may originate,
we decided to investigate a strategy for the synthesis of new α-amino acid scaffolds,
mimetics of proline, in which the COOH group is shifted to the almost unexplored position
2.48 (Fig. 11, D, E)
We reasoned that using L-ascorbic acid as a convenient and inexpensive starting material,
we could efficiently reach our goal.
L-Ascorbic acid appeared in literature as a valuable source of chiral building blocks for the
preparation of enantiopure β-lactams49 and L-hexoses50, key components of numerous
biologically active natural products.
The key intermediate L-threonic acid derivative 24 which can be efficiently obtained from
L-ascorbic acid 21 by the degradation method of Isbell and Frush,51 contains a suitably
functionalised carbon skeleton for our synthesis and the proper chirality.
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Scheme 2. Reagents and conditions: i) 2,2-dimethoxypropane, pTSA, acetone, r.t. 1h; ii) CaCO3, H2O2 35%,
Pd/C, H2O, 0°-20°C; iii) NaHCO3, Me2SO4, H2O, 40°C, 6h 70%
                                                
46 Trabocchi, A.; Cini, N.; Menchi, G.; Guarna, A. Tetrahedron Lett. 2003, 44, 3489-3492
47 Danieli, E.; Trabocchi, A.; Menchi, G.; Guarna, A. Eur. J. Org. Chem. 2005, 4372-4381
48 Lalli, C.; Trabocchi, A.; Guarna, F.; Mannino, C.; Guarna, A. Synthesis 2006, 18, 3122-3126
49 Wei, C. C.; De Bernardo, S.; Tengi, J. P.; Borgese, J.; Weigele, M. J. Org. Chem. 1985, 50, 3462-3467
50 Ermolenko, L.; Sasaki, A. J. Org. Chem. 2006, 71, 693-703
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It was obtained  upon oxidation of the protected L-ascorbic acid 22 with hydrogen
peroxide and successive esterification performed with dimethyl sulfate and sodium
bicarbonate in water. (Scheme 2)
The key intermediate 24 was converted to the corresponding triflate and then, upon
treatment with amino acetaldehyde derivative, transformed to amino acetal 25. Fmoc
protection and successive acid cyclization performed at 25°C afforded the desired bicycle
scaffold allowing a concomitant deprotection of the methyl ester functionality. (Scheme 3)
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Scheme 3. Retrosynthesis of a bicyclic α-amino acid with an endo-carboxy group from L-ascorbic acid
Formal inversion of the configuration at the C-2 stereocenter of compound 27 gives,
through a similar synthetic pathway, the corresponding diastereomer, carrying the carboxyl
group in the 2-exo position (Fig. 11, compound E).
Chloroacetate alcoholysis in mild basic conditions, followed by hydrolysis with sodium
hydrogen carbonate, permitted the inversion of configuration at the C-2 of the key
intermediate 24 in good yield.52
Interestingly, the acid conditions applied for cyclization did not allowed,  as verified in
case of diastereoisomer D, the concomitant deprotection of the methyl ester function which
had to be carried out in a further step by refluxing a solution of aqueous HCl in CH3CN for
16 hours. (Scheme 4)
The different behaviour of the two diastereoisomers led to the hypothesis that the facile
hydrolysis to give compound 27 might occur through the urethane carbonyl group
providing anchimeric assistance to the equatorial methoxycarbonyl group.
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31
i ii, iii iv v
O
N O
HOOC
Fmoc
O
N O
HOOC
FmocOO
N
COOMe
MeO
MeO
fmoc
OO
OH
COOMe
OO
OH
COOMe
3130292824
Scheme 4: Reagents and conditions: i) ClCH2COOH, PPh3, THF, 12h, then NaHCO3, MeOH 49%; ii) Tf2O,
Pyridine, DCM, -10°C, 30’; iii) aminoacetaldehyde dimethyl acetal, DIPEA, DCM, 0°C, 22h; iv) FmocCl,
2,6-lutidine, dioxane, 0°C-r.t. o/n; v) TFA, 25°C, 48h; vi) HCl, CH3CN, reflux, 16h.
In conclusion, we reported a new and efficient method for the synthesis of two proline
mimetics derived from L-ascorbic acid. The use of such an inexpensive starting material is
an advantage also for a potential multigram-scale organic synthesis.
The two new bicyclic proline analogues may find application in peptidomimetic research,
and, in particular, are suited for solid-phase organic and peptide synthesis by the Fmoc
protocol.
Since in Matrix Metallo Proteinases the catalytic zinc II ion and the selectivity pocket S1’
are close to each other, it was supposed that the presence in vicinal position of the two
main pharmacophore groups of a potential MMPI could promote a tight binding.
Therefore, a proper decoration of proline mimetics appeared as an interesting route for the
MMP-12 inhibitor research, as also evidenced by the conformationally constrained
hydroxamic acids related to proline scaffold  which are reported in literature as interesting
compounds for MMP inhibition.53
Nevertheless, we reported that the BGS based α-amino acid 10 did not show, through
NMR experiments, a detectable interaction with the MMP-12 catalytic domain (See Table
1, pag. 19); hence, we decided to get more insight into this field by changing the relative
spatial orientation of the two binding groups for a potential better fitting.
In this respect, further decoration of the two proline mimetics D and E will be
accomplished by inserting the biphenylic moiety in place of the Fmoc-protecting group and
by transforming the carboxylic acid in a better zinc binding group.
                                                
53 Cheng, M.; De B.; Almstead, N. G.; Pikul, S.; Dowty, M. E.; Dietsch, C. R.; Dunaway, C. M.; Gu, F.;
Hsieh, L. C.; Janusz, M. J.; Taiwo, Y. O.; Natchus, M. G. J. Med. Chem. 1999, 42, 5426-5436
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2.3  Solid phase N-hydroxyurea synthesis: an efficient method to convert
Fmoc-amino acids to O-protected-hydroxyureas
Over the last ten years, investigations towards new potential hydroxamate bioisosteres
were carried out either in pharmaceutical company or in academy and, in this respect, it
increased the interest on hydroxyurea derivatives as they possess metal-chelating and
redox-properties.
The simplest member of this class, N-hydroxyurea (HU), currently finds clinical use as an
antineoplastic agent for the  treatment of leukemia and other malignant tumour diseases.
HU is able to quench the tyrosil free radical at the active site of the riboncleotide reductase,
the enzyme which catalyses the conversion of the four ribonucleotides to
deoxyribonucleotides for DNA synthesis.
Although the detailed mechanism of the HU action is not still thoroughly determined, this
compound has been approved for the treatment of oncological diseases. It is well adsorbed
and it is excreted in the urine with a biological half life of less than 8 hours. Since it
inhibits DNA synthesis and has a brief duration, the drug is toxic only to cells that are
actively synthesizing DNA during the period of drug exposure.54
As HU can selectively inhibit DNA synthesis of malignant cells, it is also useful as a
treatment for sickle cell anemia55 and it inhibits HIV-1 proviral DNA synthesis in infected
cells. The antiviral effect is achieved at non toxic doses, lower than thus currently used in
human therapy.56
Since N-hydroxyurea targets a cellular enzyme instead of a viral one, no viral mutations
occur after repeated exposure to the drug and consequently it is not expected to generate
high rates of escape mutants.
Moreover, N-Hydroxyurea derivatives act as inhibitors of various metal containing
hydrolytic enzymes such as carbopeptidase A,57 carbonic anhydrase,58 matrix
                                                
54 Gao, W.-Y.; Johns, D. G.; Mitsuya, H. Mol. Pharmacol. 1994, 46, 767-772.
55 Charache, S.; Terrin, M. L.; Moore, R. D.; Dover, G. J.; Barton, F. B.; Eckert, S. V.; McMahon, R. P.;
Bonds, D. R. N. Engl. J. Med. 1995, 322, 1317-1322.
56 Lori, F.; Malykh, A.; Cara, A.; Sun, D.; Weinstein, J. N.; Lisziewicz, J.; Gallo, R. C. Science 1994, 266,
801-805.
57 Chung, S. J.; Kim, D. H. Bioorg. Med. Chem. 2001, 9, 185-189.
58 Scozzafava, A.; Supuran, C. T. Bioorg. Med. Chem. 2003, 11, 2241-2246.
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metalloproteases,59 urease60, ribonuclease61 and redox enzymes including lipoxygenase62
and ribonucleotide reductase.63
N-hydroxyureas are interesting bioisosteres of the hydroxamate pharmacophore, which has
very poor pharmacokinetic properties due to rapid hydrolysis to the corresponding, weaker
inhibitor, carboxylic acid.
In the last years some research groups carried out investigations towards potential
hydroxamate bioisosteres based on either retrohydroxamate or N-hydroxyurea moiety.
Abbott Laboratories outlined a family of N-hydroxyurea containing compounds as
bioisosteres of the hydroxamate pharmacophore that might provide potent 5-lipoxygenase
inhibitors by offering greater resistance against hydrolytic, oxidative and conjugative
metabolism.60 They also pursued a research on alternative zinc binding groups for MMP
inhibitors in order to gain a better in vivo stability by exploring different kinds of
hydroxyurea derivatives. 59a
Gallina and co-workers published the first crystallographic structure of a N-hydroxyurea
inhibitor bound into the active site of a matrix metalloprotease and compared the binding
with the catalytic zinc ion to that of hydroxamic acid derivatives.59b
The interest in identifying innovative hydroxamate bioisosteres and the various potential
applications of N-hydroxyurea derivatives in biological systems suggested the necessity to
find new synthetic procedures able to easily achieve a large collection of different N-
hydroxyurea molecules.
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Solid Phase Organic Synthesis and Combinatorial Chemistry during the last decades
provided new opportunities for medicinal chemistry research by allowing the synthesis of
molecular libraries.
Thus, the experience on N-hydroxyurea derivatives synthesis we reached during the
research of potential MMP-12 inhibitors suggested us the possibility to develop a new
SPOS method for N-hydroxyurea containing libraries.
As N-hydroxyurea libraries play an important role in the search for potential drug
candidates, an efficient and practical method for the solid phase synthesis of these
compounds is of considerable interest.
To our knowledge, there are only few examples in literature of solid phase method for N-
hydroxyurea synthesis. Bauer and co-workers described a novel linkage for the solid phase
synthesis of hydroxamic acids. In this context, they reported one example, as depicted in
Scheme 5, to evidence the chance to apply their method also to afford urea-type
hydroxamic acids by treatment with isocyanates.64
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Scheme 5. Solid phase urea-type hydroxamic acid synthesis reported by Bauer and co-workers
The use of the described linkage does not allow a direct solid phase synthesis of peptidic or
peptidomimetic N-hydroxyureas as the skeleton of the desired compounds cannot be
progressively built on the solid support. Moreover, diversification of the molecules is
limited to the readily available isocyanates and the O-nitrogen atom cannot be further
alkylated.
Thus, we developed a new easy and efficient solid phase procedure to obtain protected N-
hydroxyureas starting from Fmoc-protected amines. Activation of resin bound amino acids
with carbonyliimidazole (CDI), followed by treatment with O-benzylhydroxylamine,
provided the desired substituted N-hydroxyurea in good yield. Hydrogenolytic cleavage of
the benzyl group over 5% Pd/C easily afforded the free hydroxyurea.
                                                
64 Bauer, U.; Ho, W.-B.; Koskinen, A. M. P. Tet. Lett. 1997, 38, 7233-7236.
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Scheme 6. General solid phase organic procedure for O-Benzyl Hydroxyureas synthesis
The main advantage of this transformation over existing methods is its flexibility which
may assure a high degree of diversification. In Table 3 are depicted the two accessible
products and their potential diversifications. The L group corresponds to the main
molecular structure, consisting of peptides, peptidomimetics,  all kind of amino acids and,
mostly, all the structures bearing, besides an amine, a functional group able to bind the
solid support.
Table 3. Summary of potential diversifications permitted by the spos method
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The O-protected N-hydroxyureas synthesized reported in Table 4, were obtained following
the procedure depicted in Scheme 7.
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Scheme 7. Reagents and conditions: HMBA-AM resin; (i) Amino acid, HOBT, DIC, DMAP, DMF, r.t. o/n;
(ii) Piperidine 20% in DMF, r.t. 30’; (iii) CDI, DCM, 0°C - r.t. 1h; (iv) BnONH2, DCM, r.t. o/n; (v) cleavage
The binding of the amino acid to the HMBA-AM resin was accomplished using HOBT,
DIC and DMAP as coupling agents; after Fmoc deprotection, crude resin was treated at
0°C with a solution of CDI in DCM and the resulting mixture was allowed to reach room
temperature and stirred for 1 hour. After removing the solution, and washing the resin with
DCM and THF, BnONH2, as a free base, in DCM was added and the suspension was
shaken overnight at room temperature. (Scheme 7)
Protected hydroxyureas were cleaved off the HMBA-AM linker with a number of different
nucleophiles to yield compounds with a variety of functional groups at the C-terminus,
such as esters and amides. (Table 4)
Table 4. Synthesized O-Benzyl-Hydroxyureas and cleavage conditions
X N
H
O
OR
Entry X R Cleavage conditions Yield Puritya
31 Phe EtNH EtNH2 (70% in H2O),THF, r.t. o/n 40% - 
b
32 PheGly iBuNH iBuNH2, THF, H2O cat.,r.t. o/n 28% 50%
33 Val-Phe MeO MeOH/NH3 (9:1), 50°Co/n 83% - 
b
34
O
NH2
MeO MeOH/NH3 (9:1), 50°Co/n 44% 51%
a) Determined by HPLC analysis of crude product after cleavage from the resin; b) data not yet available
Although primary amines generally reacted affording the desired products with satisfactory
yields, amino benzoic acid failed to react according to this method probably since its low
nucleophilic character.
Also secondary amines missed the conversion to hydroxyureas through the procedure
described. Firstly, a steric hindrance issue was supposed to prevent the proline from
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reacting, however, as the experiments performed with piperidine derivatives were also
failed, a different reactivity of secondary amines from primary ones was considered as the
main reason of the missed success.
Activation of the hydroxylamine with CDI before the addition to the linked amine could be
a suitable way to accomplish the reactions performed with secondary amines as starting
materials.
An interesting behaviour of α-amino acids was found when the release of the title
compound was performed by suspending the resin in a solution of MeOH/NH3 (9:1) and
stirring overnight at 50°C. The expected methyl ester derivative was never yielded, as
shown by the absence of both the 1H and 13C NMR signals of the methyl ester in the NMR
spectrum of the molecule. The acidic O-NH group of the hydroxyurea was probably
deprotonated in the reaction environment, and the resulting anion allowed the cyclisation
with concomitant release of N-hydroxyhydantoine. (Scheme 8)
Cyclization never occurred when the cleavage was accomplished using amines as
nucleophiles and in case of peptides (as depicted in table 4); moreover, to confirm the
mechanistic hypothesis proposed, experiments will be performed with N-substituted
hydroxylamines to avoid the possibility of cyclization.
Intramolecular cyclizations often occur with amino acid ureas giving rise to hydantoine
libraries which can be evaluated for their potential as antiviral agents or tumour
proliferation inhibitors.65
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Scheme 8. Reagents and conditions: MeOH/NH3 (9:1), 50°C o/n
                                                
65 a) Chong, P. Y.; Petillo, P. A. Tet. Lett. 1999, 40, 4501-4504. b) Opačić, N.; Barbarić, M.; Zorc, B.; Cetina,
M.; Nagl, A.; Frković, D.; Kralj, M.; Pavelić, K.; Balzarini, J.; Andrei, G.; Snoeck, R.; De Clercq, E.; Raić-
Malić, S.; Mintas, M. J. Med. Chem. 2005, 48, 475-482. c) DeWitt, S. H.; Kiely, J. S.; Stankovic, C. J.;
Schroeder, M. C.; Reynolds Cody, D. M.; Pavia, M. R. Proc. Natl. Acad. Sci. USA 1993, 90, 6909-6913.
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In order to thoroughly explore the intramolecular cyclization, further experiments will be
performed starting from β-amino acids with the aim to verify the N-hydroxyhydantoine
homologs feasibility.
Finally, to provide a wider method, we started to investigate the reactivity of various resins
and hydroxylamines.
Preliminary experiments showed that this procedure is compatible with different solid
supports allowing further diversification at the C terminus. Use of acid labile resins, such
as Wang and Rink amide, leads to carboxylic acids and to free amides, respectively;
moreover, these resins may be applied when a simultaneous removal of all the acid labile
protecting groups together with the releasing from the resin is desired.
Thus, either the free or the protected with acid labile groups hydroxylamines were taken
into account.
The use of free hydroxylamine avoids the last deprotection step but it has to be further
investigated in terms of purification of the final compound.
Although treatment of the activated amino acid with OTBDMS-NH2 never yielded the
desired products, indicating its weak nucleophilic character, the synthesis of TBDMS-
protected hydroxyureas may be accomplished by inverting the reaction protocol, consisting
in the addition of the TBDMS-protected hydroxylamine pre-activated with CDI to the resin
bound free amine.
The synthesis of TBDMS-protected hydroxyureas will be useful to avoid the last
hydrogenolytic deprotection and, in case of acid labile solid support, to accomplish the
cleavage and the deprotection in only one step. These advantages are of a wide utility to
realize automated synthesis and, as a result, to generate in a short time big libraries of
organic compounds.
To conclude, since N-hydroxyureas are useful functional groups due to their metal
chelating and redox properties, it was developed a new easy and efficient synthetic method
on solid-phase to convert Fmoc-protected amino acid derivatives into O-protected N-
hydroxyureas through a carbonyldiimidazole activation of the linked amine.
Further experiments will be carried out in order to extend the class of hydroxyureas
synthesized and to optimise the procedure. Moreover, it is important to properly define the
procedures to yield either the free or the O-TBDMS protected hydroxyureas. Also,
diversification of solid phase supports may increase the class of compounds by introducing
new elements of molecular diversity.
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Once the different aspects of this SPOS procedure will be optimized, we will be able to
generate N-hydroxyurea containing molecular libraries important for drug discovery
processes.
40
2.4  Synthesis and screening of bicycle molecular scaffolds (BTAa): an
investigation towards new potential inhibitors of Sap2, a major secreted
aspartic proteinase from Candida Albicans
A research project, developed in collaboration with the “Dipartimento di malattie infettive,
parassitarie ed immunomediate” of the Istituto Superiore di Sanità in Rome, was set out
with the aim to find out new potential Sap2 inhibitors.
The project is based on two different and parallel approaches consisting in a random
screening of BTAa libraries and in a rational drug design. As it is a confidential project, the
inhibitory activity data of the molecules tested against Sap2 cannot be discuss within the
following dissertation.
Random screening of the bicyclic molecular scaffolds against Sap2 activity
One of the two approaches we developed to find out a new potential Sap2 inhibitor
consists in a random screening of the bicyclic molecules already present in our chemical
library. (Fig. 12)
The molecules were submitted to spectrophotometric tests performed at Istituto Superiore
di Sanità in Rome comparing their inhibitory activity to that of the natural inhibitor
Pepstatin A.66
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Figure 12. General formula of molecules belonging to the BTAa library
                                                
66 Experimental procedure: each assay contained 0.6 ml of 1% (w/v) BSA in 50 mM sodium citrate pH 3.2
and 0.15 ml of enzyme solution (100 mg/ml). After 30 min at 37°C 0.4 ml 10% (w/v) trichloroacetic acid
was added. The tubes were stored in ice for 30 min. and then centrifugated (1600 g) for 10 min. The
absorbance of the supernatant was read at 280 nm. Negative control: only substrate 1% BSA in citrate buffer.
Inhibition control: addition of Pepstatin A (50 mg/ml) to the mixture of enzyme and substrate.
a) Ross, I. K.; De Bernardis, F.; Emerson, G. W.; Cassone, A.; Sullivan, P. A. J. Gen. Microbiol. 1990, 136,
687-694 ; b) De Bernardis, F.; Agatensi, L.; Ross, I. K.; Emerson, G. W.; Lorenzini, R.; Sullivan, P. A.;
Cassone, A. J. Infect. Dis. 1990, 161, 1276-1283; De Bernardis, F.; Sullivan, P. A.; Cassone, A. Medical
Mycology 2001, 39, 303-313
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As the screening of all the compounds would required plenty of time, mixture of molecules
belonging to the same family of BTAa were firstly tested in order to highlight the scaffold
the most promising as Sap2 inhibitor.
Since we had first evidence that a precise class of scaffolds showed a fair inhibitory
activity, the screening of single compounds was set out to identify the best flanking units
for scaffold decoration and to get more insights into the structure-activity relationship.
Thanks to the screening results we were able to highlight some hit compounds and,
consequently, we planned some modifications on these hits in order to better define their
structural features in terms of binding. Small molecular libraries were so synthesized with
the aim to develop the procedure from hit to lead and to have further insight into the
structure-activity relationship.
Rational drug design
Sap2 displays sensitivity towards the natural inhibitor Pepstatin A, an extended
hexapeptide which acts as a tetrahedral transition state mimic by virtue of a central statine
residue containing the non scissile bond CHOH-CH2. The hydroxyl group forms hydrogen
bonds with the two catalytic aspartate side chains. Pepstatin is a non specific inhibitor of
aspartic proteases and because of its non-selectivity and lack of potency and safety it is not
an ideal agent for therapy.
Abbott laboratories developed one of the most potent inhibitor of Sap2, A-70450 which is
a pseudo hexapeptide in which the peptide bond to be hydrolysed is replaced by the
hydroxyethylene isostere.
Other noteworthy features of A-70450 include a lactam ring that severely restricts the
conformation around the P3 residue, the benzyl side chain of P3 having the R
configuration, a piperazine substituent at P4, and a n-butyl side chain at P2. (Fig. 13, A)
The three dimensional structure of a close homologue of Sap2 from C. Albicans complexed
either with the potent inhibitor A-70450 or with Pepstatin A, provided considerable insight
into the interactions of the ligand with the active site of the enzyme.67
                                                
67 a) Cutfield, S. M.; Dodson, E. J.; Anderson, B. F.; Moody, P. C. E.; Marshall, C. J.; Sullivan, P. A.;
Cutfield, J. F. Structure, 1995, 3, 1261-1271; b) Pranav Kumar, S. K.; Kulkarni, V. M. Bioorg. Med. Chem.
2002, 10, 1153-1170; c) Abad-Zapatero, C.; Goldman, R.; Muchmore, S. W.; Hutchins, C.; Stewart, K.;
Navaza, J.; Payne, C. D.; Ray, T. L. Protein Science 1996, 5, 640-652
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On the base of these studies we planned the synthesis of  new peptidomimetics as
bioisosteres of the tight-binding inhibitor A-70450. These peptidomimetics were designed
by inserting the bicycle lactam on the ketopiperazine of the target molecule. (Figure 13, B)
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Figure 13. The tight-binding inhibitor A-70450 (A) and the general formula of its potential bioisosteres based
on the BTAa scaffold (B)
The synthesis of the bicycle molecular scaffold 43 was accomplished following the same
procedure described  for compound 18. (Scheme 8) Thanks to the high reactivity of the
methyl ester in 7,68 synthesis of amides (44) was accomplished without using activating
agents with an efficient and selective procedure. Several amides were so inserted in 7 with
the aim to explore the S4 binding pocket.
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Scheme 8. Reagents and conditions: (i) NEt3, KI cat., DMF, 120°C (28%); (ii) DCM, r.t. o/n; (iii) SOCl2,
MeOH, 60°C, 1 h; (iv) SiO2/H+, toluene, reflux, 20 min (50% over three steps); N-RR’, 40°C, o/n
                                                
68 Machetti, F.; Bucelli, I.; Indiani, G.; Guarna, A. Chimie 2003, 6, 631-633
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Once highlighted the best P4 residue to insert in position 7 of the scaffold, decoration of
the opposite part of the bicycle ring with a statine derivative was accomplished.
A coupling reaction between the carboxylic acid 47 and the (3R/S)-4-amino-3-hydroxy-
butyric acid methyl ester 46 afforded the statine derivative 48 as a mixture of two
diastereoisomers. Treatment of 48 with n-butyl amine at 50°C in a mixture of THF and a
catalytic amount of water yielded the title compound 49 in good yield. (Scheme 9)
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Scheme 9. Reagents and conditions: (i) SOCl2, MeOH, r.t., o/n; (ii) PyBROP, DIPEA, DCM, r.t., o/n (44%);
(iii) nBuNH2, THF/H2O, 50°C, o/n (74%)
Comparison of the inhibition of Sap2 activity on behalf of the mixture of the two
diastereisomers 49 to that of Pepstatin A gave a first evidence of a quite good ligand-
enzyme interaction.
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Chapter 3
CONCLUSIONS
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New compounds with affinity for the catalytic domain of the MMP-12 were designed
using an integrated approach based on virtual screening and on NMR analysis. The
molecules are built around a BTAa scaffold decorated with a biphenylic moiety and with a
ZBG. The adducts provided by docking calculation enabled the identification of the
catalytic pocket of MMP-12 as the binding site for this class of compounds. The inspection
of the residues showing a significant chemical shift perturbation supports this picture, with
the lipophilic moiety fitted into S1’ cavity and the bicyclic skeleton located outside, in
front of the catalytic zinc.
Among the synthesized compounds, the scaffold 5 having the N-hydroxyurea group in
position 3 and the p-phenylbenzylcarboxy amide in position 7 showed an improved affinity
(KD = 154 µM and IC50 149 µM) for MMP-12 and some selectivity towards the other
MMPs. The X-ray structure of the catalytic domain of Human Macrophage Metalloelastase
in the presence of hydroxyurea derivative 5 gave more insight into the ligand-enzyme
interaction and appeared as a new starting point for further MMP-12 inhibitors design.
The insertion of a methylene group between the bicycle ring and the ZBG (compound 6)
provided a weak improvement in the activity even if the main binding contribution was
still determined by the insertion of the biphenylic moiety in the S1’ cavity.
Further experiments will be accomplished to better anchor the zinc chelating group in
order to find its best spatial orientation for a strong electrostatic interaction with the
catalytic ion. In this respect, the other BTAa isomers will be properly decorated and new
organic linkers will be introduced between the scaffold and the ZBG.
Moreover, a molecular library of BTAa based compounds bearing several different
lipophilic groups at position 7 will be easily generate in order to optimise the fitting in the
S1’ pocket.
Also, other fragments may be easily inserted in further positions of the bycicle skeleton to
better interact with the enzyme backbone and to selectively accommodate into the binding
pocket of MMP-12.
The synthetic versatility of BTAas, taken together with dissociation constant in a
micromolar range and fair selectivity, candidate these molecules as new compound guides
to develop more potent and selective inhibitors for MMP-12.
As conformationally constrained hydroxamic acids related to proline scaffold are
interesting compounds for MMP inhibition, the synthesis of new proline mimetics based
on the bicycle molecular scaffold was set out starting from an L-ascorbic acid derivative.
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The introduction of proper pharmacophore groups on the new α-amino acid molecular
scaffolds may represent an alternative route for the research of new potential selective
MMP-12 inhibitors.
Moreover, these new BTAa based scaffolds may find application in peptidomimetic
research, and, in particular, are suited for solid-phase organic and peptide synthesis by the
Fmoc protocol.
Since N-hydroxyureas are useful functional groups thanks to their metal chelating and
redox properties, it was developed a new easy and efficient Solid Phase Organic Synthesis
method to convert Fmoc-protected amino acids to O-protected N-hydroxyureas through the
carbonyldiimidazole activation of supported amines.
Further experiments will be carried out in order to optimise different aspects of this solid
phase procedure and with the aim to extend the class of N-hydroxyureas which may be
synthesized.
In this respect, it will be properly defined the procedure to yield either the free or the O-
TBDMS protected hydroxyureas. Indeed, the use of the free or the O-TBDMS protected
hydroxylamine is of major utility as it allows to avoid the hydrogenolytic cleavage of the
benzyl protecting group and, consequently, leads to easier procedures which may be
applied in automated systems for the generation of combinatorial libraries.
Also, diversification of solid phase supports may increase the class of compounds which
can be synthesized and so enhance the degree of molecular diversification.
Once the different aspects of this SPOS procedure will be optimized, we will be able to
generate N-hydroxyurea containing molecular libraries important for drug discovery
processes.
The random screening of BTAa derivatives, followed by a more focussed screening of
scaffolds with specific structural features, allowed to complete a thorough collection of
data about Sap2 inhibition and to gain a preliminary and deep knowledge concerning the
structure activity relationship.
On parallel, according to a rational drug design, a bioisostere of the tight binding inhibitor
A-70450 was synthesized and its fair inhibitory activity suggested that the insertion of the
bicycle scaffold on the ketopiperazine ring of the target molecule may actually be an
interesting route for new Sap2 inhibitors research.
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Further investigations will be done to optimise the bioisostere structure improving its
binding with the catalytic site of the enzyme.
First of all, the two diastereoisomers which were synthesized as a mixture of compounds
will be separated and then tested again. It is well known, in fact, that the stereochemistry of
the central statine residue is extremely important for a good binding.
Moreover, a small peptidomimetic library varying the P2’ residue (see Fig. 13, B) will be
generate with the aim to improve specificity.It is reported, in fact, that the fitting of the P2’
grouop into the corresponding  pocket may contribute in the selectivity towards the other
aspartyl proteases, such as Cathepsin D and Renin.
Either the random screening or the rational drug design approach suggested that BTAa,
thanks to their synthetic versatility, may represent a new type of scaffold to design new
aspartyl protease inhibitors.
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EXPERIMENTAL
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Melting points are uncorrected and were measured on microscope RCH Kofler apparatus.
Chromatographic purifications were performed with silica gel 60 (0.040-0.063 mm), unless
otherwise stated, using flash column techniques; all TLC development was performed on
silica gel coated (Merck Silica gel 60 F254, 0.25 mm) sheets. IR spectra were recorded on
Perkin Elmer 881 spectrophotometer. 1H and 13C NMR spectra were obtained on a Varian
Gemini 200 (200 MHz for 1H and 50.33 MHz for 13C) instrument or a Varian Mercury 400
(400 MHz for 1H and 100 MHz for 13C) instrument using tetramethylsilane as internal
standard and the chemical shifts were reported in δ (ppm) units. EI Mass spectra were
carried out at 70 eV ionizing voltage by direct introduction on a QMD 1000 Carlo Erba
instrument, whereas ESI-MS spectra were carried out on LTQ Thermo Finnigan
instrument. Microanalysis were carried out on Perkin Elmer 240C elemental analyser.
Optical rotation measurements were performed on JASCO DIP-370 digital polarimeter. All
reactions requiring anhydrous conditions were carried out under N2 atmosphere and were
performed in oven-dried glassware.
HPLC analysis were performed with a Beckman-Gold system, mobile phase: H2O/TFA
0.001% and CH3CN/TFA 0.001%; Jasco U.V. detector, λ = 230 nm; Alltech Econosphere
riverse phase C18 5U column (250 mm × 4.6 mm), 20 µL loader. The program used was:
CH3CN/TFA 10%-20 min-90%-5 min-90%-5 min-10%, rate flow 1 mL/min.
Preparation of acid silica gel (SiO2/H2SO4): SiO2 (29 g) was suspended in CH2Cl2 (400 ml)
with 12 g of H2SO4 and left under quickly magnetic stirring for 40 min. The suspension
was then concentrated at low pressure.
(2,2-Dimethoxy-ethylamino)-acetic acid methyl ester (14)
A suspension containing glycine methyl ester hydrochloride (4 g,  31.8 mmol), NEt3  (4.43
mL, 31.8 mmol), dimethoxy acetaldehyde (2.85 mL, 31.5 mmol) and Pd/C 10% in 100 mL
of MeOH was stirred at room temperature overnight under H2 atmosphere. Filtration
through a pad of celite afforded the crude product. Further purification by column
chromatography (Silica gel, AcOEt/EP 4:1) yielded the pure 14 as a colorless oil (3.2 g,
59% yield).
1H-NMR (CDCl3, 200 MHz): δ = 4.41 (t, J = 5.3 Hz, 1H), 3.68 (s, 3H), 3.40 (s, 2H), 3.33
(s, 6H), 2.71 (d, J = 5.6 Hz, 2H); 13C-NMR (CDCl3, 200 MHz): δ = 172.5 (s), 103.8 (d),
53.84 (q), 51.82 (q), 50.75 (t), 50.62 (t); IR (CHCl3) 3336, 2834, 1737, 1356 MS m/z 118
(5.98), 102 (4.49), 75 (100).
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R-hydroxy-[(2R, 6R/S)-(6-methoxy-4-methoxycarbonylmethyl-3-oxo-morpholin-2-
yl)]-acetic acid methyl ester (17)
To a suspension of (R,R)-2,3-di-O-acetyltartaric anhydride (15) (3.9 g, 18 mmol) in dry
DCM (18 ml) was added, at 0 °C and under N2 atmosphere, a solution of 14 (3.2 g, 18
mmol) in dry DCM (9 ml). The reaction mixture was stirred at room temperature
overnight. After evaporation of the solvent, the crude product was dissolved in MeOH (30
ml) and thionyl chloride (1.12 mL, 15 mmol) was added drop wise at 0 °C. The mixture
was then allowed to reach 60 °C and stirred for 2 h. The solvent was removed and the
crude product was isolated as a yellow oil and used without further purification in the next
step. Purification of the crude product by column chromatography (Silica gel, AcOEt/EP
4:1) afforded the pure 17 as an oil.
[α]D26 + 121.03 (c 1.1, CHCl3); 1H-NMR (CDCl3, 200 MHz): δ = 4.89 (d, J = 3 Hz, 1H),
4.82 (s, 1H), 4.54 (s, 1H), 4.25 (d, J = 17.2 Hz, 1H), 3.96 (d, J = 17.2 Hz, 1H), 3.77 (s, 3H),
3.68 (s, 3H), 3.46-3.39 (m, 1H), 3.43 (s, 3H), 3.21 (d, J = 12.2 Hz, 1H); 13C-NMR (CDCl3,
200 MHz): δ = 172.1 (s), 168.5 (s), 165.9 (s), 94.78 (d), 72.20 (d), 71.32 (d), 55.13 (q),
52.75 (q), 52.35 (q), 51.26 (t), 47.86 (t); IR (CHCl3) 3545, 1745, 1665, 1266, 1141 cm-1;
MS m/z 291 (M, 0.63), 260 (11.55), 232 (26.05), 58 (100); Anal. Calcd for C11H17NO8
(291.26): C, 45.36; H, 5.88; N, 4.81. Found: C, 44.03; H, 6.03; N, 4.44.
(1R, 5S, 7R)-3-methoxycarbonylmethyl-2-oxo-6,8-dioxa-3-aza-bicyclo[3.2.1]octane-7-
carboxylic acid methyl ester (18)
A solution of 17 (5.2 g, 18 mmol) in toluene (25 ml) was quickly added to a refluxing
suspension of SiO2/H2SO4 (4 g) in toluene (50 ml). The mixture was allowed to react for
30’ and then one-third of the solvent was distilled off. The hot reaction mixture was
filtered through a pad of NaHCO3 and, after evaporation of the solvent, the crude product
was purified by flash chromatography (Silica gel, AcOEt/EP 2:1) affording 18 as a
colorless oil (800 mg, 17% yield over three steps).
[α]D24 -49.9 (c 1.13, CHCl3); 1H-NMR (CDCl3, 200 MHz): δ = 5.83 (d, J = 2.2 Hz, 1H),
4.83 (s, 1H), 4.68 (s, 1H), 4.08-3.86 (AB system, 2H), 3.69 (s, 3H), 3.64 (s, 3H), 3.52 (dd,
J1 = 11.6 Hz, J2 = 2.2 Hz, 1H), 3.21 (d, J1 = 11.6 Hz, 1H); 13C-NMR (CDCl3, 200 MHz): δ
= 171.6 (s), 168.9 (s), 168.2 (s), 165.9 (s), 99.88 (d), 77.59 (d), 72.23 (d), 52.90 (q), 52.81
(t), 52.40 (q), 46.16 (t); IR (CHCl3) 1749, 1683, 1136, 1108 MS m/z 259 (M, 5.39), 200
51
(13.01), 102 (100); Anal. Calcd for C10H13NO7 (259.22): C, 46.34; H, 5.06; N, 5.40.
Found: C, 45.60; H, 5.37; N, 5.44.
(1R, 5S, 7R)-7-[(Biphenyl-4-ylmethyl)-carbamoyl]-2-oxo-6,8-dioxa-3-aza-
bicyclo[3.2.1]oct-3-yl}-acetic acid methyl ester (19)
A solution containing 18 (80 mg, 0.3 mmol) and p-phenylbenzyl amine (68 mg, 0.37
mmol) in DCM (200 µl) was stirred at 40°C overnight. After evaporation of the solvent,
the crude product was purified by flash chromatography (Silica gel, DCM/MeOH 20:1)
affording 19 as a white solid (108 mg, 88% yield).
Mp 193-196 °C; [α]D24 +13.8 (c 0.98, CHCl3); 1H-NMR (CDCl3, 200 MHz): δ = 7.60-7.31
(m, 9H), 6.86 (bs, 1H), 5.87 (d, J = 2.2 Hz, 1H), 5.07 (s, 1H), 4.76 (s, 1H), 4.52 (d, J 5.8
Hz, 2H), 4.20 (d, J = 17.6 Hz, 1H), 3.94 (d, J = 17.6 Hz, 1H), 3.75 (s, 3H), 3.60 (dd, J1 =
11.8 Hz, J2 = 1.8 Hz, 1H), 3.31 (d, J1 = 11.8 Hz, 1H); 13C-NMR (CDCl3, 200 MHz): δ =
168.1 (s), 167.9 (s), 165.9 (s), 140.3 (s), 136.2 (s), 128.5, 127.8, 127.2, 127.1, 126.7 (d),
99.52 (d), 79.08 (d), 77.08 (d), 52.39 (t), 52.15 (q), 45.70 (t), 42.74 (t); IR (CHCl3) 1748,
1686, 1520  MS m/z 410 (M, 19.24), 182 (71.98), 167 (100); Anal. Calcd for C22H22N2O6
(410.43): C, 64.38; H, 5.40; N, 6.83. Found: C, 64.21; H, 5.86; N, 5.46.
(1R,5S,7R)-3-{2-[(benzyloxy)amino]-2-oxoethyl}-2-oxo-6,8-dioxa-3-
azabicyclo[3.2.1]octane-7-carboxamide (20)
To a solution of  19 (220 mg, 0.54 mmol) in MeOH/THF (2:3) was added LiOH (96 mg,
2.3 mmol) and the resulting mixture was stirred at room temperature overnight.
The reaction mixture was then diluted with aqueous 5% HCl  and the organic solvent was
evaporated under reduced pressure; the aqueous layer was then washed with CHCl3 to
extract the product. The resulting organic layer was dried over Na2SO4 and, after
evaporation of the solvent, 100 mg (0.25 mmol) of the crude ((1R,5S,7R)-7-{[(1,1'-
biphenyl-4-ylmethyl)amino]carbonyl}-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-3-yl)acetic
acid were dissolved at 0°C in a solution containing HOBT (41 mg, 0.5 mmol), DIC (77 µL,
0.5 mmol), benzylhydroxylamine (31 mg, 0.25 mmol) and DIPEA (150 µL, 0.88 mmol) in
DCM (2 mL). The resulting solution was allowed to reach room temperature and was
stirred overnight. The reaction mixture was then washed with a saturated solution of
NaHCO3, aqueous 5% KHSO4 and brine and dried over Na2SO4. After evaporation of the
solvent the crude product was purified by flash chromatography (silica gel, AcOEt/EP 3:1)
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to afford 20 (50 mg, 42% yield in two steps) which was directly used in the next step
without a complete characterization.
1H-NMR (CDCl3, 200 MHz): δ 7.61-7.50 (m, 5H), 7.48-7.24 (m, 9H), 7.00-6.88 (m, 1H),
5.86 (s, 1H), 5.04 (s, 1H), 4.78 (s, 1H), 4.58-4.44 (m, 2H), 3.90-3.73 (m, 2H), 3.61-3.46
(m, 1H), 3.33-3.12 (m, 1H); MS m/z 410 (6.15), 379 (1.73), 339 (1.44), 167 (100).
(1R,5S,7R)-3-Hydroxycarbamoylmethyl-2-oxo-6,8-dioxa-3-aza-bicyclo[3.2.1]octane-7-
carboxylic acid (biphenyl-4-ylmethyl)-amide (6)
A stirred solution of 20 (50 mg, 0.1 mmol) in THF (3 mL) was submitted to
hydrogenolysis over 10% Pd/C at 1Atm, at room temperature, over night. After separation
of the catalyst by filtration through a pad of celite, the solvent was evaporated affording 6
as a white solid (25 mg, 61% yield).
1H-NMR (DMSO, 200 MHz): δ 8.77-8.61 (m, 1H), 7.65-7.43 (m, 4H), 7.40-7.27 (m, 5H),
6.03 (bs, 1H), 4.67 (s, 1H), 4.60 (s, 1H), 4.32 (d, J = 5.4 Hz, 2H), 3.39-3.42 (m, 2H), 3.22-
3.13 (m, 2H); MS m/z 410 (3.31), 395 (0.65), 338 (28.8), 167 (100).
(2S)-2-({[(benzyloxy)amino]carbonyl}amino)-N-ethyl-3-phenylpropanamide (31)
HMBA-AM resin 25 (200 mg, 0.17 mmol) was preswelled in 3 mL of DMF. After
draining off the solvent, a solution of Fmoc-L-PheOH (263 mg, 0.68 mmol), HOBT (92
mg, 0.68 mmol), DIC (107 µL, 0.68 mmol) and a catalytic amount of DMAP in 3 mL of
DMF was added and the resulting suspension was stirred overnight at room temperature.
The solution was then filtered off and the derivatized resin was washed with DMF. Next,
the resin was shaken for 30 min. at r.t. with 20% piperidine in DMF to carry out Fmoc
deprotection and after draining off the solution it was thoroughly washed with DMF,
MeOH and DCM. Crude resin was then treated at 0°C with a solution of CDI (83 mg, 0.51
mmol) in 3 mL of DCM and the resulting mixture was allowed to reach room temperature
and stirred for 1 hour. After removing of the solution and washing with DCM and THF,
BnONH2 (63 mg, 0.51 mmol), as a free base, in 2 mL of DCM was added to the resin and
the mixture was shaken overnight at r.t. Then the solution was filtered off and the resin was
washed with DCM and THF. Releasing of the title compound was performed by
suspending the resin in a solution of EtNH2 (70% in H2O, 1.5 mL) in THF and stirring at
room temperature overnight. After filtering out the solution and eluting the resin with THF,
the combined organic layers were evaporated under reduced pressure affording a pale
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yellow oil. Chromatographic purification (AcOEt/EP, 2:1) afforded pure 31 as a white
solid (23 mg, 40% yield).
1H-NMR (CDCl3, 200 MHz): δ 7.37-7.18 (m, 10H), 7.08 (s, 1H), 6.14 (d, J = 8 Hz, 1H),
5.55 (bs, 1H), 4.76-4.64 (AB system, 2H), 4.42 (pseudo q, J = 7.3 Hz, 1H), 3.22-3.09 (m,
3H), 2.94 (dd, J1 = 13.6 Hz, J2 = 7.8 Hz, 1H), 0.97 (t, J = 7.4 Hz, 3H); 13C-NMR (CDCl3,
200 MHz): δ 170.2 (s), 159.1 (s), 136.5 (s), 135.0 (s), 129.3, 128.8, 128.6, 127.0 (d), 78.68
(t), 54.75 (d), 38.61 (t), 34.48 (t), 14.72 (q); MS m/z 341 (7.46), 91 (100).
 (2S)-2-({[(benzyloxy)amino]carbonyl}amino)-N-isobutyl-2-phenylethanamide (32)
Compound 32 was prepared according to the procedure described for 31 starting from
HMBA-AM resin 25 (100 mg, 0.08 mmol) and Fmoc-L-PheGly-OH (119 mg, 0.32 mmol).
Releasing of the title compound was performed by suspending the resin in a solution of
isobutyl amine (165 µL, 1.66 mmol) in 2 mL of THF and a catalytic amount of water and
stirring at room temperature overnight. After filtering out the solution and eluting the resin
with THF, the combined organic layers were evaporated under reduced pressure affording
a pale yellow oil. The purity obtained after cleavage was 50%, as indicated by HPLC
analysis. Further chromatographic purification (AcOEt/EP, 1:1) afforded pure 32 as a
colorless oil (8 mg, 28% yield).
1H-NMR (CDCl3, 200 MHz): δ 7.42-7.34 (m, 5H), 7.33-7.22 (m, 5H), 7.01 (d, J = 4 Hz,
1H), 6.96 (s, 1H), 5.88 (bs, 1H), 5.30 (d, J = 7 Hz, 1H), 4.89-4.77 (AB system, 2H), 3.16-
2.92 (m, 2H), 1.75-1.58 (m, 1H), 0.79 (d, J = 6.6 Hz, 6H); 13C-NMR (CDCl3, 200 MHz): δ
169.6 (s), 158.9 (s), 138.2 (s), 135.2 (s), 129.4, 128.9, 128.8, 128.7, 128.2, 127.0 (d), 78.77
(t), 57.51 (d), 47.20 (t), 28.56 (d), 20.08 (q); MS m/z 355(3.70), 255 (24.15), 233 (7.74),
149(56.11), 91 (100).
({[(benzyloxy)amino]carbonyl}amino)-Phe-Val-OMe (33)
HMBA-AM resin 25 (200 mg, 0.17 mmol) was preswelled in 3 mL of DMF. After
draining off the solvent, a solution of Fmoc-L-Val-OH (231 mg, 0.68 mmol), HOBT (92
mg, 0.68 mmol), DIC (107 µL, 0.68 mmol) and a catalytic amount of DMAP in 3 mL of
DMF was added and the resulting suspension was stirred overnight at room temperature.
The solution was then filtered off and the derivatized resin was washed with DMF. Next,
the resin was shaken for 30 min. at r.t. with 20% piperidine in DMF to carry out Fmoc
deprotection. After draining off the solution and washing the resin with DMF, Fmoc-L-
Phe-OH (263 mg, 0.68 mmol) was loaded onto the resin using the same coupling
54
conditions described above. After Fmoc deprotection, the resin was filtered off and
thoroughly washed with DMF, MeOH and DCM. Crude resin was then treated at 0°C with
a solution of CDI (83 mg, 0.51 mmol) in 3 mL of DCM and the resulting mixture was
allowed to reach room temperature and stirred for 1 hour. After removal of the solution and
washing with DCM and THF, BnONH2 (63 mg, 0.51 mmol), as a free base, in 2 mL of
DCM was added to the resin and the mixture was shaken overnight at r.t. Then the solution
was filtered off and the resin was washed with DCM and THF. Releasing of the title
compound was performed by suspending the resin in a solution of MeOH/NH3 (9:1, 10
mL) and stirring overnight at 50°C. After filtering out the solution and eluting the resin
with MeOH, the combined organic layers were evaporated under reduced pressure
affording a pale yellow oil. Chromatographic purification (AcOEt/EP, 1:1) afforded pure
33 (60 mg, 83% yield) as a colorless oil.
1H-NMR (CDCl3, 200 MHz): δ 7.40-7.17 (m, 11H), 6.63 (d, J = 8.4 Hz, 1H), 6.22 (d, J =
7.6 Hz, 1H), 4.69 (s, 2H), 4.60 (pseudo q, J = 7.3 Hz, 1H), 4.43 (dd, J1 = 8.6 Hz, J2 = 5.6
Hz, 1H), 3.68 (s, 3H), 3.04 (d, J = 7 Hz, 2H), 2.17-2.04 (m, 1H), 0.84 (t, J = 6.8 Hz, 6H);
13C-NMR (CDCl3, 200 MHz): δ 171.6 (s), 170.7 (s), 159.2 (s), 136.4 (s), 135.0 (s), 129.3,
129.1, 128.8, 128.6, 128.6, 126.9 (d), 78.73 (t), 57.47 (d), 54.65 (d), 52.17 (q), 38.27 (t),
31.29 (d), 19.00 (q), 17.98 (q); MS m/z 427 (6.42), 297 (5.93), 91 (100).
Methyl 4-[({[(benzyloxy)amino]carbonyl}amino)methyl]benzoate (34)
Compound 34 was prepared according to the procedure described for 31 starting from
HMBA-AM resin 25 (100 mg, 0.08 mmol) and 4-((fmoc-amino)methyl)benzoic acid (119
mg, 0.32 mmol). Releasing of the title compound was performed by suspending the resin
in a solution of MeOH/NH3 (9:1, 10 mL) and stirring overnight at 50°C. After filtering out
the solution and eluting the resin with MeOH, the combined organic layers were
evaporated under reduced pressure affording a pale yellow oil. The purity obtained after
cleavage was 51%, as indicated by HPLC analysis. Further chromatographic purification
(AcOEt/EP, 1:1) afforded pure 34 (11 mg, 44%).
1H-NMR (CDCl3, 200 MHz): δ 7.97 (d, J = 8.2 Hz, 2H), 7.36 (s, 5H), 7.20 (d, J = 8.2 Hz,
2H), 7.06 (s, 1H), 5.93 (bs, 1H), 4.80 (s, 2H), 4.42 (d, J = 6.2 Hz, 2H), 3.91 (s, 3H); 13C-
NMR (CDCl3, 200 MHz): δ 159.4 (s), 143.2 (s), 134.8 (s), 129.6, 129.0, 128.7, 128.5,
126.8 (d), 78.48 (t), 51.86 (q), 42.88 (t) MS m/z 314 (0.14), 283 (2.35), 164 (4.58), 91
(100).
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(5S)- 3-Benzyloxy-5-isopropyl-imidazolidine-2,4-dione (35)
Compound 35 was prepared according to the procedure described for 31 starting from
HMBA-AM resin 25 (200 mg, 0.17 mmol) and Fmoc-L-ValOH (231 mg, 0.68 mmol).
Releasing of the title compound was performed by suspending the resin in a solution of
MeOH/NH3 (9:1, 10 mL) and stirring overnight at 50°C. After filtering out the solution and
eluting the resin with MeOH, the combined organic layers were evaporated under reduced
pressure affording a pale yellow oil. Chromatographic purification (AcOEt/EP, 1:1)
afforded pure 35 as a white solid (19 mg, 45%).
1H-NMR (CDCl3, 200 MHz): δ 7.51-7.43 (m, 2H), 7.40-7.31 (m, 3H),  5.71 (s, 1H), 5.13
(s, 2H), 3.82 (d, J = 3.8 Hz, 1H), 2.24-2.09 (m, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.83 (d, J =
7.0 Hz, 3H); 13C-NMR (CDCl3, 200 MHz): δ 167.5 (s), 154.3 (s), 133.3 (s), 129.8, 129.3,
128.4 (d), 79.31 (t), 60.44 (d), 30.24 (d), 18.51 (q), 16.10 (q); MS m/z 141 (0.80), 100
(10.39), 91 (100).
(5S)- 5-Benzyl-3-benzyloxy-imidazolidine-2,4-dione (36)
Compound 36 was prepared according to the procedure described for 31 starting from
HMBA-AM resin 25 (200 mg, 0.17 mmol) and Fmoc-L-PheOH (263 mg, 0.68 mmol).
Releasing of the title compound was performed by suspending the resin in a solution of
MeOH/NH3 (9:1, 10 mL) and stirring overnight at 50°C. After filtering out the solution and
eluting the resin with MeOH, the combined organic layers were evaporated under reduced
pressure affording a pale yellow oil. Filtration over a pad of Amberlyst 15 afforded 45 mg
of 36 as a pale yellow oil.
1H-NMR (CDCl3, 200 MHz): δ 7.46-7.10 (m, 10H), 6.02 (s, 1H), 4.98-4.87 (AB system,
2H), 4.14 (dd, J1 = 8.2 Hz, J2 = 4 Hz, 1H), 3.18 (dd, J1 = 13.8 Hz, J2 = 4 Hz, 1H), 2.79 (dd,
J1 = 14 Hz, J2 = 8.2 Hz, 1H); 13C-NMR (CDCl3, 200 MHz): δ 167.2 (s), 153.2 (s), 134.4
(s), 133.2 (s), 129.9, 129.4, 129.2, 128.8, 128.5, 128.4 (d), 79.35 (t), 56.24 (d), 37.71 (t).
(2 S)-2-(2’,2’-dimethoxy-ethylamino)-4-methyl-pentanoic acid methyl ester (39)
A solution containing L-leucine methyl ester hydrochloride (2.9 g, 16 mmol), 2-bromo-
1,1-dimethoxy ethane (1.9 ml, 2.7 g, 16 mmol), NEt3 (6.7 ml, 48 mmol) and a catalytic
amount of KI in DMF (190 mL) was stirred at 120 °C for 3 days. The reaction mixture was
concentrated under reduced pressure, diluted with water and extracted with DCM. The
organic layer was then washed with brine, dried over Na2SO4 and evaporated. The crude
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product was purified by column chromatography  (silica gel, AcOEt/EP 1:1) to afford 39
as a yellow oil (1.2 g, 32% yield).
[α]D24 -3.32 (c 1.02, CHCl3); 1H-NMR (CDCl3, 200 MHz): δ 4.38 (t, J = 6 Hz, 1H), 3.65
(s, 3H), 3.30 (s, 3H), 3.29 (s, 3H), 3.24 (t, J = 6 Hz, 1H), 2.68 (dd, J1 = J2 = 6 Hz, 1H), 2.52
(dd, J1 = J2 = 6 Hz, 1H), 1.71-1.55 (m, 2H), 1.44-1.37 (m, 2H), 0.86 (d, J = 4 Hz, 3H), 0.83
(d, J = 4 Hz, 3H); 13C-NMR (CDCl3, 200 MHz): δ 175.9 (s), 103.6 (d), 59.94 (d), 54.02
(q), 53.08 (q), 51.67 (q), 49.26 (t), 42.78 (t), 24.99 (d), 22.76 (q), 22.48 (q); MS m/z 233
(0.46), 202 (7.16), 174 (33.8), 158 (13.9), 75 (100); IR (CHCl3) 3000-2831, 1729, 1464-
1435, 1130, 1065 cm-1; Anal. Calcd for C11H23NO4 (233.30): C, 56.63; H, 9.94; N, 6.00.
Found: C, 57.49; H, 9.90; N, 6.24.
(2S)-2-[(2’S)-2’-(hydroxy-methoxycarbonyl-methyl)-6-methoxy-3-oxo-morpholin-4-
yl]-4-methyl pentanoic acid methyl ester (42)
To a suspension of (S,S)-2,3-di-O-acetyltartaric anhydride (40) (1 g, 4.7 mmol) in dry
DCM (4.5 ml) was added, at 0 °C and under N2 atmosphere, a solution of 39 (1 g, 4.7
mmol) in dry DCM (2.5 ml). The reaction mixture was stirred at room temperature
overnight. After evaporation of the solvent, the crude product was dissolved in MeOH (8
ml) and thionyl chloride (292 µL, 4 mmol) was added drop wise at 0 °C. The mixture was
then allowed to reach 60 °C and stirred for 2 h. The solvent was removed and the crude 42
was isolated as a yellow oil and used without further purification in the next step.
(1R, 5S, 7S)-3-[(1’S)-1’-Methoxycarbonyl-3’-methyl-butyl]-2-oxo-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-7-carboxylic acid methyl ester (43)
A solution of 42 (1.63 g, 4.7 mmol) in toluene (8 ml) was quickly added to a refluxing
suspension of SiO2/H2SO4 (1 g) in toluene (12 ml). The mixture was allowed to react for
30’ and then the one-third of the solvent was distilled off. The hot reaction mixture was
filtered through a pad of NaHCO3 and, after evaporation of the solvent, the crude product
was purified by flash chromatography (Silica gel, AcOEt/EP 1:2) affording 43 as a white
solid (730 mg, 50% yield over three steps).
[α]D24 22.0 (c 1.01, MeOH); 1H-NMR (CDCl3, 200 MHz): δ 5.88 (d, J = 2 Hz, 1H), 5.09 (t,
J = 8 Hz, 1H), 4.87 (s, 1H), 4.59 (s, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 3.50 (dd, J1 = 12 Hz, J2
= 2 Hz, 1H), 3.11 (dd, J1 = 12 Hz, 1H), 1.67-1.60 (m, 2H), 1.46-1.32 (m, 1H), 0.88 (s, 3H),
0.84 (s, 3H); 13C-NMR (CDCl3, 200 MHz): δ 170.8 (s), 168.7 (s), 165.6 (s), 100.0 (d),
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77.77 (d), 77.35 (d), 52.82 (d), 52.43 (q), 52.26 (q), 48.06 (t), 36.62 (t), 24.75 (d), 23.29
(q), 21.28 (q); MS m/z 315 (11.0), 256 (100), 240 (3.94); Anal. Calcd for C14H21NO7
(315.33): C, 53.33; H, 6.71; N, 4.44. Found: C, 52.99; H, 5.58; N, 4.79.
General procedure for amides (44) synthesis
A solution containing 43 (1 g, 3.2 mmol) and the desired amine (63 mmol) was stirred at
60°C over night. The reaction mixture was then concentrated under reduced pressure and
the crude product was purified by column chromatography  (silica gel, DCM/ MeOH 20:1)
to afford derivatives 44 in good yield.
In the following NMR characterization the signals corresponding to R and R’ groups are
omitted. 1H-NMR (CDCl3, 200 MHz): (mixture of two rotamers) δ 5.79 (d, 1H, J = 1.4
Hz), 5.06-4.94 (m, 1H), 5.02 (s, 1H), 4.82 (s, 1H, minor rotamer), 4.71 (s, 1H, major
rotamer), 3.62 (s, 3H, minor r.), 3.61 (s, 3H, major r.), 3.55-3.20 (m, 1H), 3.09 (d, J = 11.8
Hz, 1H), 1.67-1.34 (m, 3H), 0.86 (d, J = 4.8 Hz, 3H), 0.84 (d, J = 5.8 Hz, 3H); 13C-NMR
(CDCl3, 200 MHz) (mixture of two rotamers): δ 171.1 (s, minor r.), 170.8 (s, major r.),
167.6 (s, minor r.), 166.8 (s, major r., r.), 164.9 (s, minor r.), 164.8 (s, major r.), 99.59 (d,
major r.), 99.47 (d, minor r.), 77.99 (d), 76.44 (d), 52.67 (q), 52.40 (d, major r.), 52.19 (d,
minor r.), 48.58 (t, major r.), 47.68 (t, minor r.), 36.76 (t, major r.), 35.84 (t, minor r.),
24.71 (d), 23.20 (q), 21.52 (q).
4-Amino-3-hydroxy-butyric acid methyl ester hydrochloride salt (46)
A solution containing (2S)-4-amino-2-hydroxy-butyric acid (2 g, 16.8 mmol) and thionyl
chloride (1.84 mL, 25 mmol) in MeOH (160 ml) was stirred at room temperature
overnight. Removal of the solvent afforded 46 as a pale yellow oil (2.5 g, 88% yield).
1H-NMR (D2O, 200 MHz): δ 4.18-4.04 (m, 1H), 3.53 (s, 3H), 3.01 (dd, J1 = 13.2 Hz, J2 =
2.6 Hz, 1H), 2.87-2.72 (m, 1H), 2.59-2.33 (m, 2H); 13C-NMR (D2O, 200 MHz): δ 172.9
(s), 64.40 (d), 52.49 (q), 43.90 (t), 39.26 (t); MS m/z 134 (0.75), 56 (100).
(3R/S)-3-Hydroxy-4-{(2S)-4-methyl-2-[(1R, 5S, 7S)-2-oxo-7-(R, R’)-6,8-dioxa-3-aza-
bicyclo[3.2.1]oct-3-yl]-pentanoylamino}-butyric acid methyl ester (48)
To a solution of  46 (37 mg, 0.22 mmol) in DCM (4 ml) were added, under N2 atmosphere
and at 0°C, PyBROP (102 mg, 0.22 mmol), carboxylic acid 47 (0.22 mmol) and DIPEA
(85 µl, 0.5 mmol). The resulting solution was allowed to reach room temperature and was
stirred overnight.
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The reaction mixture was then washed with a saturated solution of NaHCO3, aqueous 5%
KHSO4, brine and dried over Na2SO4. After evaporation of the solvent the crude product
was diluted in AcOEt and left for three hours at 4°C in order to let precipitate the PyBROP.
Purification by flash chromatography (silica gel, AcOEt) afforded 48 as a colorless oil.
In the following NMR characterization the signals corresponding to R and R’ groups are
omitted. 1H-NMR (CDCl3, 200 MHz): δ 6.81-6.69 (m, 1H), 5.86 (d, J = 2.4 Hz, 1H), 5.14
(d, J = 2.4 Hz, 1H), 5.10-4.81 (m, 2H), 4.16-4.05 (m, 1H), 3.69 (s, 3H), 3.56-3.20 (m, 4H),
2.46 (d, J = 5.6 Hz, 2H), 1.77-1.41 (m, 3H), 0.96-0.88 (m, 6H); 13C-NMR (CDCl3, 200
MHz): δ 172.5 (s), 170.2 (s), 168.1 (s), 165.3 (s), 99.62 (d), 78.00 (d), 67.27 (d), 53.69,
53.01 (d, 2 diastereoisomers), 52.02 (q), 48.58 (t), 47.54 (t), 38.70 (t), 36.33 (t), 24.68 (d),
23.09 (q), 22.04 (q).
4-Methyl-2-[(1R, 5S, 7S)-2-oxo-7-(R, R’)-6,8-dioxa-3-aza-bicyclo[3.2.1]oct-3-yl]-
pentanoic acid (3-butylcarbamoyl-2-hydroxy-propyl)-amide (49)
A solution containing 48 (40 mg, 0.08 mmol) and n-butyl amine (168 µL, 1.7 mmol) in a
mixture of THF (200 µl) and two drops of H2O is stirred at 50°C for three days. Filtration
of the reaction mixture on Amberlyst 15 and further purification by column
chromatography (Silica gel, DCM/MeOH 20:1) afforded 49 as a colorless oil.
In the following NMR characterization the signals corresponding to R and R’ groups are
omitted. 1H-NMR (CDCl3, 200 MHz): δ 6.81-6.68 (m, 1H), 6.41-6.22 (m, 1H), 5.90, 5.86
(s, 1H, mix of two diastereoisomers), 5.14-4.81 (m, 3H), 4.13-3.92 (m, 1H), 3.66-3.35 (m,
4H), 3.36-3.02 (m, 2H), 2.28 (d, J = 5.2 Hz, 2H), 1.88-1.20 (m, 7H), 0.97-0.87 (m, 9H);
13C-NMR (CDCl3, 200 MHz): δ 171.5 (s), 170.2 (s), 168.0 (s), 164.8 (s), 99.58 (d), 77.95
(d), 67.94 (d), 54.10, 53.87 (d, 2 diastereoisomers), 47.57 (t), 44.55 (t), 39.44 (t), 36.39 (t),
34.92 (t), 31.60 (t), 24.86 (d), 23.10 (q), 22.03 (q), 20.24 (t), 13.92 (q).
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Available online 8 August 2006Abstract—Starting from 3-aza-6,8-dioxa-bicyclo[3.2.1]octane scaffold (BTAa) a virtual library of molecules was generated and
screened in silico against the crystal structure of the Human Macrophage Metalloelastase (MMP-12). The molecules obtaining high
score were synthesized and the affinity for the catalytic domain of MMP-12 was experimentally proved by NMR experiments. A
BTAa scaffold 20 having a N-hydroxyurea group in position 3 and a p-phenylbenzylcarboxy amide in position 7 showed a fair inhi-
bition potency (IC50 = 149 lM) for MMP-12 and some selectivity towards five different MMPs. These results, taken together with
the X-ray structure of the adduct between MMP-12, the inhibitor 20 and the acetohydroxamic acid (AHA), suggest that bicyclic
scaffold derivatives may be exploited for the design of new selective matrix metalloproteinase inhibitors (MMPIs).
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Matrix metalloproteinases (MMPs) are a family of zinc-
dependent, calcium containing, endopeptidases involved
in extracellular matrix degradation and, consequently,
they play a crucial role in physiological processes such
as tissue remodelling and healing of wounds.1 As the
upregulation of MMPs is involved in many inflammato-
ry, malignant and degenerative diseases,2 attempts to de-
sign and develop inhibitors that may modulate their
regulation have become of great interest.3–5
The main requirement for a small molecule to be an
effective metalloproteinase inhibitor (MMPI) is the pres-
ence of both a functional group capable of chelating the
active-site zinc ion and a lipophilic residue able to fit
into the S01 pocket.
4 Hydroxamic acid is the most popu-
lar zinc binding group (ZBG) for MMPIs even if some
authors report that it is fast metabolized in vivo6,7 and0968-0896/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2006.07.028
Keywords: Metalloproteinases; Inhibitors; BTAa; NMR spectroscopy.
* Corresponding author. Tel.: +39 055 4573481; fax: +39 055
4573569; e-mail: antonio.guarna@unifi.itit contributes to increase toxicity due to its low metal
binding selectivity.8
The inhibitors designed up to date usually bind the ac-
tive site on the catalytic domain providing nanomolar
dissociation constants.3,4 However, several inhibitors
exhibit a poor selectivity as a consequence of the high
structural similarity among the members of the MMP
family.9 Even if the low specificity does not prevent
the use in vivo, it raises a lot of side effects and it also
limits the dose that may be daily administered.10,11 As
a consequence, the search of new potent and selective
MMP inhibitors still represents an important pharma-
ceutical target.
Even if the expensive high-throughput screening of small
molecule libraries is one of the most popular approaches
in pharmaceutical research, alternative strategies, based
on docking calculation and rational drug design, may be
adopted if the 3D structure of the target is solved.12–14
A new class of molecular heterocyclic scaffolds (BTAa)
based on 3-aza-6,8-dioxa-bicyclo[3.2.1]octane skele-
ton,15 which can be decorated with a ZBG and a
C. Mannino et al. / Bioorg. Med. Chem. 14 (2006) 7392–7403 7393lipophilic residue, was chosen to design selective MMP-
12 inhibitors (Fig. 1).
The main feature of these scaffolds is their tridimension-
al bicyclic skeleton generated by combination of sugar
and amino acid derivatives. Their synthesis includes
only few steps starting from commercially available
enantiopure precursors and a stereochemistry control
can be accomplished in each step of the synthesis. As
dipeptide isosteres, BTAas are compounds with poten-
tial biological activity and their use as central core of
pharmaceutical targets is convenient as a high number
of positions can be functionalized leading to molecular
diversity. Limited flexibility can be advantageous to cor-
rectly direct the pharmacophore side chains and it is also
useful for computational analysis. In addition, as amino
acids, they have full compatibility with the conditions
required for solid-phase synthesis.15,16
All these properties, together with fair solubility and low
molecular weight, were considered in scaffold selection.
Diversification of BTAas by easy decoration with differ-
ent functional groups may generate virtual libraries
which may be screened in silico in order to identify
new hit compounds for further lead discovery. Even if
the binding energy provided by docking programs does
not reflect exactly the real binding affinity, its value al-N OO
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R
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3
5
7
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Scheme 1. Reagents and conditions: (i) NaBH4, MeOH, 25 C, 16 h; (ii) C
toluene, reflux, 20 min, 41% (over the four steps); (v) BH3ÆMe2S, THF, 25 Clows to score the docking results in order to identify a
class of potential ligand.17
Moreover, the experimental assessment of the affinity of
few selected molecules outlined by docking results gives
the chance to correlate binding energies and binding
constants improving the prediction reliability. A com-
bined use of virtual screening and experimental determi-
nation of the binding affinity suggested that the BTAas
may represent a new type of scaffolds to design a new
class of MMPIs.2. Chemistry
The synthesis of 3-biphenyl-4-ylmethyl-3-aza-6,8-dioxa-
bicyclo[3.2.1]octane-7-carboxylic acid methyl ester (p-
PhBn-BTGOMe) (8) was carried out following a proce-
dure previously reported for similar compounds and is
briefly reported below Scheme 1.12
Reductive alkylation of aminoacetal 1 with biphenyl-4-
carbaldehyde (2) and NaBH4 afforded in good yield
the aryl aminoacetal 3 which was subsequently convert-
ed into the amide 5 by treatment with (R,R) tartaric
anhydride18 4. Crude 5 was treated with thionyl chloride
in MeOH affording cyclic acetal 6, which was submitted
to the acid-catalyzed cyclization to give 7 in 40% yield
over the four steps. Reduction of amide 7 with
BH3Me2S furnished the corresponding amine 8 in
70% yield (Scheme 1).
Basic hydrolysis of 7 and acid-catalyzed hydrolysis of 8
gave, respectively, the free acids 9 and 10 in good yields.
A peculiar feature of BTAas is the demonstrated high
reactivity of their methyl ester function towards amines,
although simple esters are usually not very reactive to-
wards direct aminolysis.19 Owing to this, hydroxamic
acids 11 and 12were easily prepared bymixing the scaffoldO OO
AcO OAc
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and NEt3 in CHCl3 at room temperature (Scheme 2).
To prepare the model compound 15 having a N-hy-
droxyurea as zinc-binding group, piperidine 13 was
treated with triphosgene and then with benzyl-hydroxyl-
amine and NEt3 affording compound 14. The debenzyl-
ated product 15 was readily obtained by mild
hydrogenolytic cleavage of the protecting group over
5% Pd/C at 1 atm (Scheme 3).20
A new BTAa scaffold 20 having the N-hydroxyurea
group in position 3 and the p-phenylbenzylcarboxy
amide in position 7 was then prepared. Due to the high
reactivity of ester 16, the biphenyl derivative 17was easily
and quantitatively prepared by stirring the starting mate-
rial at 60 C with a neat excess of amine. Debenzylation
was carried out by refluxing a solution of 17 in MeOH
in the presence of ammonium formate and catalytic Pd/
C. Then, compound 18 was activated with carbonyldiim-HN
OEt
O i, ii
N
HN
O
13 14OBn
Scheme 3. Reagents and conditions: (i) (CCl3O)2CO, CH2Cl2, from 0 C to 2
(1 atm), 5% Pd/C, AcOEt, 25 C, 12 h, quantitative.
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Scheme 4. Reagents and conditions: (i) p-PhBn–NH2, 60 C, 12 h, 93%; (ii)
THF, 25 C, 12 h, 60%; (iv) H2 (1 atm), 5% Pd/C, THF, 25 C, 12 h, 68%.idazole (CDI) and treated with O-benzylhydroxylamine,
as a free base, providing the substituted N-hydroxyurea
19 in 60% yield after crystallization.21 Hydrogenolytic
cleavage of the benzyl group over 5% Pd/C afforded the
desired final compound 20 (Scheme 4).3. Results and discussion
The availability of high-resolution structure of the
MMP-12 catalytic domain22,23 provided the possibility
to employ a structure-based approach to design and
screen a virtual library.
A biphenylic moiety and a hydroxamic (or carboxylic)
acid were chosen as good substituents24 to be introduced
in different position of BTAa and hundreds of structures
were so generated and tested in silico for their affinity to
the catalytic domain of MMP-12.
The hits with the highest score were selected and, among
them, compounds 9-12 were synthesized due to their
higher feasibility. In this class of molecules the scaffold
supports the biphenylic moiety in front of the ZBG.
The Autodock binding model predicted a deep insertion
of the biphenyl group into the S01 cavity though the coor-
dination geometry of the ZBG appeared not to be
optimized.
Dissociation constants (KD) of compounds 9–12 were
calculated through 15N–1H HSQC experiments.25 In
addition, compounds 21–24, already present in our
chemical library, were submitted to the same experi-
ments in order to compare the results and support the
docking model.
Moreover, the inhibitory activity (IC50) of compounds
9–12 was measured by enzymatic assays.26
The values of KD and IC50 for the tested compounds
9–12 and 20–24 are reported in Table 1.OEt
O iii
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Table 1. Calculated MMP-12 binding affinity (KD) and inhibition potency (IC50)
N OO
R''
R
R'
X
Compound X R R 0 R00 MMP-12 KD
c MMP-12 IC50
d (lM)
9 O p-PhBn H COOH P1 mM 954
10 H, H p-PhBn H COOH P1 mM 835
11 O p-PhBn H CONHOH P500 lM 425
12 H, H p-PhBn H CONHOH P500 lM 399
20 H, H HONHCO H CONH–p-PhBn 154 lM 149
21a O Bn H COOH P10 mM —
22a H, H Bn H COOH P10 mM —
23a O Bn H CONHOH P10 mM —
24a H, H p-PhBn COOH H not detec.b —
N
OEt
O
NH
O
HO
15
3.4 mM —
aCompounds previously described.15,29,30
b No detectable interaction found by NMR.
cDissociation constants measured through 15N–1H HSQC NMR experiments.
d Inhibition potency measured by fluorescence enzymatic assays.
Figure 2. (A) Surface model of the MMP-12 showing the catalytic zinc and the S01 pocket. (B) Residues of the MMP-12 affected by chemical shift
perturbation upon the addition of 12.
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the binding may be crucial to prove a direct interaction
with the catalytic site and, consequently, for the optimi-
zation of the process, NMR-based strategies were also
used to localize the binding site on the target.27 The
identification of the binding site was easily performed
analyzing the protein resonance chemical shifts in
1H–15N HSQC spectra, recorded either in presence or
in absence of the ligand.28
The pattern of the shifts was similar for all ligands. Sev-
eral residues forming the S01 cavity, one or more zinc
binding histidines and the neighbouring amino acids
are strongly influenced by the presence of this class of
molecules. As example, a ribbon representation of
MMP-12 is shown in Figure 2. The NHs showing signif-
icant chemical shift perturbation upon the addition of
compound 12 are highlighted. The affected amino acids
nicely define the ligand binding site that is the same for
all the designed compounds in agreement with the dock-
ing results. Only few differences were found among themembers of this class. In particular, the NH cross-peak
of His218 was only weakly shifted by lactams 9 and 11
with respect to compound 12.
The analysis of the results summarized in Table 1 sug-
gests that the bicyclic skeleton of BTAa should be com-
patible with the metalloelastase catalytic domain, but
the activity is strongly modulated by the type and
position of the substituents. Hydroxamic acids 11, 12
(IC50 = 425 lM, 399 lM, respectively) are more potent
than the carboxylic ones 9, 10 (IC50 = 954 lM,
835 lM, respectively). The affinity observed within this
series seemed to be highly dependent on the presence
of the biphenylic moiety: the replacement of the biphe-
nylmethyl with a benzylic-protecting group resulted in
a loss of binding affinity, so compounds 21 and 22
(KDP 10 mM) are almost inactive; and the introduc-
tion of the hydroxamic moiety in position 7 did not
restore the activity (see compound 23). Otherwise, the
presence of the ZBG and the lipophilic residue in vicinal
position decreases the binding affinity as demonstrated
Figure 3. Expansion of 1H–15N HSQC spectrum showing the shift of
the His218 backbone NH upon the addition of increasing concentra-
tion of compound 15.
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were found by NMR.
With these results in our hands we decided to focus our
efforts on the design of new derivatives with improved
affinity. A deeper penetration in the S01 cavity was possi-
ble moving the biphenyl group quite far from the scaf-
fold. Due to the high reactivity of the BTAa methyl
ester, it was synthetically very easy to introduce the
biphenylic moiety in 7 through an amide bond. As a
consequence, the best anchoring point for the ZBG
resulted in the N-3 giving rise to a N-hydroxyurea (com-
pound 20). The use of this functional group as metal
chelator in MMP inhibitors has been previously report-
ed6 and recently validated by a X-ray structure.31
In order to determine the affinity of the N-hydroxyurea
moiety, the model compound 15 was tested in silico and
synthesized (see Scheme 3).
The in silico model suggested that the interaction of 15
with the active site is limited to the catalytic zinc and
to the entrance into the S01 subsite. The structure of
the adduct shows the same coordination scheme of the
hydroxamic acid which is able both to chelate the
active-site zinc ion and to provide a hydrogen bond
interaction with the enzyme backbone. The protonated
oxygen atom (O4) is involved in a strong hydrogen bond
with carboxylate Oe2 of Glu219, while the NH shows
weaker electrostatic interaction with the Ala181 carbon-
yl oxygen.
To determine the binding affinity for the MMP-12 cata-
lytic domain, we analyzed the alteration of the chemical
shifts induced on 2D 1H–15N HSQC upon the titration
with the N-hydroxyurea derivative 15. The fit of the
experimental data provided a dissociation constant of
3.4 mM. The binding mode predicted in silico is sup-
ported by the pattern of resonance frequencies shifted
as a consequence of the interaction. The NH signal cor-
responding to His218 is strongly affected by millimolar
concentration of the ligand (Fig. 3), while only few
residues forming the S01 cavity are weakly influenced.
Since the metal binding capability of the N-hydroxyurea
was confirmed, the new scaffold 20 was synthesized. (see
Scheme 4)
The 1H–15N HSQC spectra for 20 showed a pattern of
shifts similar to compounds 9–12 indicating for all these
molecules the same binding site (Fig. 4).
A different effect on the zinc binding histidine with re-
spect to the N-hydroxyurea prototype is probably pres-
ent since the shift perturbation involved mainly His222
instead of His218. The fit of Dd as a function of the
ligand concentration provided a KD of 154 lM, in good
agreement with the IC50 value of 149 lM obtained by
the enzymatic assay (Fig. 4).
To probe the selectivity towards MMP-12, N-hydroxy-
urea 20 was also tested by fluorescence enzymatic exper-
iments for the inhibition of collagenases (MMP-1,MMP-8, MMP-13), matrilysin 1 (MMP-7) and strom-
elysin 2 (MMP-10) and the corresponding data are sum-
marized in Table 2. Compound 20 is a fairly selective
MMP-12 inhibitor since it possesses limited activity
against the other MMPs especially the MMP-1 and
MMP-7. These two enzymes differ from other MMP
family members since they have a relatively small S01
pocket which presumably cannot accommodate the
large biaryl substituent.
Although compound 20 exhibits an improved affinity
towards MMP-12, nevertheless the micromolar value
of KD demonstrates that all the planned interactions
are not optimized. The X-ray structure of the MMP-
12–20 complex (PDB code: 2HU6) provided a direct
inspection on ligand–protein interactions (Fig. 5A).
As correctly predicted by the NMR studies the mole-
cule binds the metalloelastase at the catalytic site, fit-
ting the biaryl moiety into the S01 pocket. The
electron density of the inhibitor is well defined because
it is held in place by two hydrogen bonds with Pro238
and Leu181 of the enzyme backbone. However, the
contribution of the hydroxyurea to the binding is abso-
lutely negligible since it points towards the exterior of
the active site and does not interact with the catalytic
zinc ion.
Noteworthy, the zinc ion is coordinated by the weak
inhibitor acetohydroxamic acid (AHA) present, as stabi-
lizer, in the crystallization buffer. This would suggest that
the lack of interaction between the hydroxyurea and the
catalytic zinc, evidenced in the crystal structure, is due
to the competition with the high concentration of AHA.
In order to investigate this point, an energy minimiza-
tion of the ligand was performed after removing AHA
from the PDB and blocking the biaryl group in the crys-
tal structure conformation. The AMBER-8 minimized
model indicates that the hydroxyurea function could
Figure 4. (A) 1H–15N HSQC spectrum of MMP-12 catalytic domain in absence (black) and in presence (light grey) of compound 20 (500 lM). (B)
Expansion of 1H–15N HSQC spectrum showing the shift of the His222 backbone NH upon the addition of increasing concentration of compound 20.
Table 2. MMP enzyme inhibition potency of compound 20 measured by enzymatic assay
Compound IC50 (lM)
MMP-1 MMP-7 MMP-8 MMP-10 MMP-12 MMP-13
20 1180 1510 513 865 149 778
Figure 5. (A) Crystal structure of MMP-12–20 adduct; the zinc ion is coordinated by AHA (Green). (B) AMBER-8-minimized model of MMP-12–20
adduct.
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actions with the zinc binding site are not well defined as
in the case of AHA (Fig. 5B).
Therefore, these data suggest that the anchoring point
and/or the length of the ZBG are not optimized and fur-
ther studies have to be carried out in order to design a
nanomolar inhibitor.4. Conclusion
New compounds with affinity for the catalytic domain
of the MMP-12 were designed using an integrated
approach based on virtual screening and on NMR
analysis. The molecules are built around a BTAa scaf-fold functionalized with a biphenyl moiety and with a
ZBG.
The adducts provided by docking calculation enabled
the identification of the catalytic pocket of MMP-12 as
the binding site for this class of compounds. The inspec-
tion of the residues showing a significant chemical shift
perturbation supports this picture, with the lipophilic
moiety fitted into S01 cavity and the bicyclic skeleton
located outside, in front of the catalytic zinc.
Among the synthesized compounds, the scaffold 20 hav-
ing the N-hydroxyurea group in position 3 and the
p-phenylbenzylcarboxy amide in position 7 showed an
improved affinity (KD = 154 lM and IC50 149 lM) for
MMP-12 and some selectivity towards the other MMPs.
7398 C. Mannino et al. / Bioorg. Med. Chem. 14 (2006) 7392–7403The X-ray structure of the catalytic domain of Human
Macrophage Metalloelastase in the presence of hydroxy-
urea derivative 20 gave more insight into the ligand–en-
zyme interaction and appeared as a new starting point
for further MMP-12 inhibitors’ designing.
New fragments may be easily inserted in the bicyclic
scaffold to better interact with the enzyme backbone
and to selectively accommodate into the binding pocket
of MMP-12. Therefore, the synthetic versatility of
BTAas, taken together with dissociation constant in
micromolar range and fair selectivity, candidate these
molecules as new compound guides to develop more po-
tent and selective inhibitors for MMP-12.5. Methods
Docking calculations were performed using the
Lamarckian genetic algorithm (LGA) of the program
Autodock 3.032 which, using principles of natural evolu-
tion mutations and cross-over, probes the designed mol-
ecules on the three-dimensional structure of the target
macromolecule. In this work, the crystal structure of
the catalytic domain of MMP-12 (PDB code: 1RMZ),
processed by AutoDockTools, was used as target pro-
tein. The three-dimensional structures of the designed li-
gands, generated by Chem3D Pro program, were
minimized by semiempirical calculations and the Gastei-
ger-Marsili charges33 assigned by the program Babel. In
order to include all the active site, a box of
19.75 · 19.75 · 19.75 A˚3, centred near the catalytic zinc
and with a grid spacing of 0.275 A˚, was selected as dock-
ing space. A total of 50 runs were performed for each
ligand and the results were ranked according to the
docking energy.
The cDNA, encoding the fragment Gly106-Gly263
(F171D mutant)34 of the macrophage metalloelastase,
was cloned into the pET21 vector (Novagen) using NdeI
and BamHI as restriction enzymes and then transfected
into E. coli strain BL21 Codon Plus cells. Uniform 15N-
labelled protein was expressed by induction with
0.5 mM IPTG at 37 C for 4 h in M9 minimal media
containing 15 mM (15NH4)2SO4.
The inclusion bodies, containing the protein, were solu-
bilized in a buffered solution with 20 mM Tris–HCl and
8 M urea at pH 8. The protein was then purified with a
size-exclusion chromatography (Pharmacia HiLoad
Superdex 75 16/60) in 6 M urea and 50 mM sodium ace-
tate. A second step of purification was performed on
cation exchange column Mono-S (Pharmacia) using a
linear gradient of NaCl up to 0.5 M.
The protein was refolded by using a multi-step dialysis
against solution containing 50 mM Tris–HCl (pH 7.2),
10 mM CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl and decreas-
ing concentrations of urea (from 4 M up to 2 M). The
last two dialyses were performed against solution
containing 20 mM Tris–HCl (pH 7.2), 5 mM
CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl and 200 mM of
hydroxamic acid (AHA). The catalytic domains ofMMP-1 (Val101-Pro269), MMP-7 (Tyr100-Lys272),
MMP-8 (Met100-Gly262), MMP-10 (Phe99-Gly263,
F170N mutant), MMP-13 (Tyr104-Pro269) were ex-
pressed, purified and refolded according to the protocol
already described for MMP-12, with minor
modifications.
1H–15N HSQC experiments, implemented with the sen-
sitivity enhancement scheme,35 were recorded at 298 K
on a Bruker DRX 700 operating at proton nominal fre-
quency of 700.21 MHz. The NMR experiments were
performed on samples containing 0.1 mM of 15N-
enriched MMP-12 in 10 mM Tris–HCl buffer, 10 mM
CaCl2, 0.1 mM ZnCl2, 0.3 M NaCl and 0.2 M acetohy-
droxamic acid at pH 7.2.
The compounds were evaluated for their ability to inhib-
it the hydrolysis of fluorescence-quenched peptide
substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
(Biomol, Inc.). The assays were performed in 50 mM
HEPES buffer, containing 10 mM CaCl2, 0.05% Brij-
35, at pH 7, using 1 nM of proteolytic enzyme (catalytic
domains of MMP-1, MMP-7, MMP-8, MMP-10,
MMP-12, MMP-13) and 1 lM of peptide. The enzyme
was incubated at 25 C with increasing concentration
of inhibitor and the fluorescence (excitationmax
328 nm; emissionmax 393 nm) was measured for 3 min
after the addition of the substrate using a Varian
Eclipse fluorimeter. Fitting of rates as a function of
inhibitor concentration provided IC50 values (see Table
1). The inhibitor N-isobutyl-N-[4-methoxyphenylsulfo-
nyl]glycyl hydroxamic acid (Biomol, Inc.) was used as
control.
Crystals of human MMP-12, already containing AHA
from the refolding process, grew at 20 C from a
0.1 M Tris–HCl, 30% PEG 6000, 200 mM AHA,
1.0 M LiCl2 solution at pH 8.0 using the vapour diffu-
sion technique. The final protein concentration was
about 10 mg/ml. Soaking procedure was implemented
in order to allow the inhibitor binding; 20 was added
in the powdered form directly into the drop using a nee-
dle and was left incubating for a few days. The data were
measured exploiting synchrotron radiation at the beam-
line ID23-1 (ESRF, Grenoble, France). The dataset was
collected at 100 K and the crystal used for data collec-
tion was cryo-cooled without any cryo-protectant treat-
ment. The crystal diffracted up to 1.3 A˚ resolution and
belongs to space group C2 (a = 51.25 A˚, b = 60.18 A˚,
c = 53.97 A˚, a = c = 90, b = 114.59) with one molecule
in the asymmetric unit, a solvent content of about 50%
and a mosaicity of 0.7. The data were processed in all
cases using the program MOSFLM36 and scaled using
the program SCALA37 with the TAILS and SECOND-
ARY corrections on (the latter restrained with a TIE
SURFACE command) to achieve an empirical absorp-
tion correction.
Table 3 shows the data collection and processing statis-
tics for all datasets. The structure was solved using the
molecular replacement technique; the model used was
that of the MMP-12–AHA adduct (1Y93) from where
the inhibitor, all the water molecules and ions were
Table 3. Data collection and anisotropic refinement statisticsa
Space group C2
Cell dimensions (A˚,) A = 51.25, b = 60.18,
c = 53.97, b = 114.59
Resolution (A˚) 49.10–1.32
Unique reflections 34825 (5291)
Overall completeness (%) 99.0 (98.8)
Rsym(%) 5.3 (27.6)
Multiplicity 3.1 (2.9)
I/(rI) 8.6 (2.5)
Wilson plot B-factor (A˚2) 10.55
Rcryst/Rfree (%) 16.2/18.7
Protein atoms (excluding hydrogens) 1238
Ions 5
Ligand atoms 33
Water molecules 300
rmsd bond lengths (A˚) 0.006
rmsd bond angles () 1.0
Mean B-factor (A˚2) 13.90
a The numbers in parentheses refer to values in the highest resolution
shell.
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molecule within the crystallographic unit cell was deter-
mined with standard Patterson search techniques38,39 as
implemented in the program MOLREP.40,41 The aniso-
tropic refinement was carried out using REFMAC5.42
In between the refinement cycles the model was subject-
ed to manual rebuilding by using XtalView.43 The same
program was used to model the inhibitors. Water mole-
cules were added by using the standard procedures with-
in the ARP/WARP suite.44 The stereochemical quality
of the refined models was assessed using the program
Procheck.45 The Ramachandran plot is of very good
quality.6. Experimental
Melting points are uncorrected and were measured on
microscope RCH Kofler apparatus. Chromatographic
purifications were recorded with silica gel 60 (0.040–
0.063 mm), unless otherwise stated, using flash column
techniques; all TLC development was performed on
silica gel coated (Merck Silica gel 60 F254, 0.25 mm)
sheets. IR spectra were recorded on Perkin-Elmer
881 spectrophotometer. 1H and 13C NMR spectral
analyses were obtained on a Varian Gemini 200
(200 MHz for 1H and 50.33 MHz for 13C) instrument
or a Varian Mercury 400 (400 MHz for 1H and
100 MHz for 13C) instrument using tetramethylsilane
as internal standard and the chemical shifts were
reported in d (ppm) units. EI mass spectral analyses
were carried out at 70 eV ionizing voltage by direct
introduction on a QMD 1000 Carlo Erba instrument,
whereas ESI-MS spectra were carried out on LTQ
Thermo Finnigan instrument. Microanalyses were car-
ried out on Perkin Elmer 240 C elemental analyser.
Optical rotation measurements were performed on
JASCO DIP-370 digital polarimeter. All reactions
requiring anhydrous conditions were carried out under
N2 atmosphere and were performed in oven-dried
glassware.Preparation of acid silica gel (SiO2/H2SO4): SiO2 (29 g)
was suspended in CH2Cl2 (400 ml) with 12 g of H2SO4
and left under vigorous magnetic stirring for 40 min.
The suspension was then concentrated at low pressure.
6.1. Biphenyl-4-yl-methyl-(2,2-dimethoxy-ethyl)-amine
(3)
A solution containing 2,2-dimethoxy-ethylamine
(14.4 g, 137 mmol) and biphenyl-4-carbaldehyde
(25 g, 137 mmol) in MeOH (300 ml) was stirred at
room temperature for 2.5 h. NaBH4 was then slowly
added at 0 C and the reaction mixture was stirred
at room temperature overnight. Once the reaction
was completed MeOH was evaporated in vacuo and
the crude residue was suspended in ethyl acetate,
washed with water and dried over Na2SO4. The result-
ing product was used in next step without further
purification. Purification by column chromatography
using ethyl acetate/petroleum ether (1:1) as eluent
afforded the pure 3 as a colourless oil.
1H NMR (CDCl3): d 7.62–7.26 (m, 9H), 4.53 (t, 1H,
J = 5.5 Hz), 3.86 (s, 2H), 3.39 (s, 6H), 2.80 (d, 2H,
J = 5.6 Hz); 13C (CDCl3): d 140.9, 139.9, 139.1 (s),
128.7–127.0 (d), 104.0 (d), 54.10 (t), 53.68 (t), 50.70
(q); MS m/z 271 (M+, 15), 167 (100); IR (CHCl3)
3323, 2829 cm1; Anal. Calcd for C16H19NO2 (257.1):
C, 74.68; H, 7.44; N, 5.44. Found: C, 74.75; H, 7.52;
N, 5.65.
6.2. (2R,6R/S)-(4-Biphenyl-4-yl-methyl-6-methoxy-3-
oxo-morpholin-2-yl)-(R)-hydroxyacetic acid methyl ester
(6)
To a suspension of (R,R)-2,3-di-O-acetyltartaric anhy-
dride (4) (30 g, 137 mmol) in dry DCM (120 ml) was
added, at 0 C and under N2 atmosphere, a solution
of 3 (37 g, 137 mmol) in dry DCM (60 ml). The reac-
tion mixture was stirred at room temperature over-
night. After evaporation of the solvent, the crude
product was dissolved in MeOH (230 ml) and thionyl
chloride (8.5 ml, 116 mmol) was added dropwise at
0 C. The mixture was then allowed to reach 60 C
and stirred for 2 h. The solvent was removed and
the crude product was isolated as a yellow oil and
used without further purification in the next step.
Purification of the crude product by column chroma-
tography (ethyl acetate/petroleum ether 2:1) afforded
6 as a white solid.
Mp 115–120 C; ½a26D +111.1 (c 1.3, CHCl3); 1H NMR
(CDCl3): d 7.60–7.26 (m, 9H), 4.96 (s, 1H), 4.87 (s,
1H), 4.84 (d, 1H, J = 14 Hz), 4.64 (s, 1H), 4.54 (d, 1H,
J = 14 Hz), 3.85 (s, 3H), 3.58 (dd, 1H, J1 = 14 Hz,
J2 = 3.2 Hz), 3.39 (s, 3H), 3.16 (d, 1H, J = 14 Hz);
13C
NMR (CDCl3): d 172.4 (s), 165.4 (s), 140.6, 140.4,
134.5 (s), 128.7, 128.2, 127.4, 127.2, 127.0 (d), 95.95
(d), 72.28 (d), 71.60 (d), 55.15 (q), 52.89 (q), 49.65 (t),
49.55 (t); MS m/z 385 (M+, 58), 167 (100); IR (CHCl3)
3545, 1745, 1654 cm1; Anal. Calcd for C21H23NO6
(385.2): C, 65.44; H, 6.02; N, 3.63. Found: C, 65.03;
H, 6.22; N, 3.27.
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dioxa-bicyclo[3.2.1]octane-7-carboxylic acid methyl ester
(7)
A solution of 6 (52 g, 137 mmol) in toluene (200 ml) was
quickly added to a refluxing suspension of H2SO4/SiO2
(29 g) in toluene (400 ml). The mixture was allowed to
react for 20 min and one-third of the solvent was dis-
tilled off. The hot reaction mixture was filtered through
a short layer of NaHCO3 and, after evaporation of the
solvent, the crude product was purified by column chro-
matography using ethyl acetate/petroleum ether (2:1) as
eluent and affording 7 (20 g, 41% over four steps) as a
white solid.
Mp 160–165 C; ½a25D 40.5 (c 1.0, CHCl3); 1H NMR
(CDCl3): d 7.60–7.26 (m, 9H), 5.89 (d, 1H,
J = 2.2 Hz), 5.01 (s, 1H), 4.79 (s, 1H), 4.66–4.52 (Ab sys-
tem, 2H), 3.81 (s, 3H), 3.42 (dd, 1H, J1 = 2.2 Hz,
J2 = 12 Hz), 3.17 (d, 1H, J = 12 Hz);
13C NMR
(CDCl3): d 169.0 (s), 165.4 (s), 140.9, 140.4, 134.2 (s),
128.7, 128.4, 127.6, 127.4, 127.0 (d), 100.1 (d), 77.83
(d), 77.73 (d), 52.93 (q), 51.23 (t), 48.21 (t); MS m/z
353 (M+, 11), 167 (100); IR (CHCl3) 1756, 1674 cm
1;
Anal. Calcd for C20H19NO5 (353.1): C, 67.98; H, 5.42;
N, 3.96. Found: C, 67.54; H, 5.42; N, 3.69.
6.4. (1S,5S,7R)-3-Biphenyl-4-ylmethyl-3-aza-6,8-dioxa-
bicyclo[3.2.1]octane-7-carboxylic acid methyl ester (8)
BH3ÆSMe2 (0.403 ml, 4.2 mmol) was added dropwise to
a cooled (0 C) solution of 7 (1 g, 2.8 mmol) in dry
THF under N2 atmosphere and the resulting mixture
was stirred at room temperature overnight. Once the
reaction was completed EtOH (2 ml) and H2O were add-
ed and the resulting mixture was washed with OEt2. The
organic layer was dried over Na2SO4 and concentrated
in vacuo. The crude product was purified by column
chromatography using ethyl acetate/petroleum ether
(3:1) as eluent to afford 8 (670 mg, 70%) as a white solid.
Mp 130–134 C; ½a24D 57.0 (c 1.0, CHCl3); 1H NMR
(CDCl3): d 7.63–7.36 (m, 9H), 5.66 (s, 1H), 4.86 (s,
1H), 4.66 (s, 1H), 3.78 (s, 3H), 3.70–3.50 (AB system,
2H), 2.87 (pseudo t, 2H, J = 11.6 Hz), 2.56 (dd, 1H,
J1 = 1.6, J2 = 11.2 Hz), 2.35 (d, 1H, J = 12 Hz);
13C
NMR (CDCl3): d 171.4 (s), 140.7, 140.2, 136.3 (s),
129.2, 128.7, 127.2, 127.1, 127.0 (d), 101.4 (d), 77.00
(d), 76.07 (d), 61.16 (t), 56.44 (t), 54.85 (t), 52.54 (q);
MS m/z 339 (M+, 23), 167 (100); IR (CHCl3) 1753,
1733 cm1; Anal. Calcd for C20H21NO4 (339.2): C,
70.78; H, 6.24; N, 4.13. Found: C, 70.34; H, 6.41; N,
4.00.
6.5. (1S,5S,7R)-3-Biphenyl-4-ylmethyl-2-oxo-3-aza-6,8-
dioxa-bicyclo[3.2.1]octane-7-carboxylic acid (9)
A solution containing 7 (85 mg, 0.24 mmol) and LiOH
(25 mg, 0.6 mmol) in a mixture of MeOH and THF in
a 2:1 ratio (5 ml) was stirred overnight at room temper-
ature. The reaction mixture was then acidified with 5%
HCl and the organic solvents were removed in vacuo.
The remaining aqueous layer was washed with DCMand the resulting organic phase was dried over Na2SO4
and concentrated under reduced pressure to afford 9
(65 mg, 80%) as a white solid.
Mp 186–195 C; 1H NMR (DMSO): d 7.66–7.27 (m,
9H), 5.95 (s, 1H), 4.89 (s, 1H), 4.80 (s, 1H), 4.60–4.42
(AB system, 2H), 3.38 (d, 1H, J = 14 Hz), 3.10 (d, 1H,
J = 14); 13C NMR (DMSO): d 170.6 (s), 165.7 (s),
140.1, 139.7, 135.9 (s), 129.3, 128.7, 127.8, 127.4, 127.0
(d), 99.85 (d), 77.62 (d), 77.50 (d), 51.64 (t), 47.39 (t);
MS m/z 339 (M+, 17), 167 (100); Anal. Calcd for
C19H17NO5 (339.1): C, 67.25; H, 5.05; N, 4.13. Found:
C, 66.86; H, 5.06; N, 4.04.
6.6. (1S,5S,7R)-3-Biphenyl-4-ylmethyl-3-aza-6,8-dioxa-
bicyclo[3.2.1]octane-7-carboxylic acid (10)
A solution containing 8 (80 mg, 0.23 mmol) and aq. HCl
4 M (0.800 ml) was stirred overnight at room tempera-
ture. The product was then freeze-dried affording 10
(75 mg, 90%) as a white solid.
Mp 158–165 C; 1H NMR (DMSO): d 11.18 (br s, 1H),
7.72–7.67 (m, 5H), 7.48–7.35 (m, 4H), 5.83 (s, 1H), 5.45
(s, 1H), 4.97 (s, 1H), 4.34 (m, 2H), 3.60–3.48 (m, 1H),
3.42–3.22 (m, 1H), 3.20–2.96 (m, 2H); 13C NMR
(DMSO) (carboxylic carbon not detected): d 139.7,
132.8 (s), 129.4–127.1 (d), 101.0 (d), 75.03 (d), 74.31
(d), 59.47 (t), 53.19 (t), 52.86 (t); MS m/z 325 (M+,
21), 167 (100); IR (KBr) 3406, 2355, 1741 cm1; Anal.
Calcd for C19H20ClNO4 (361.11): C, 63.07; H, 5.57; N,
3.87. Found: C, 62.88; H, 5.71; N, 3.75.
6.7. (1S,5S,7R)-3-Biphenyl-4-ylmethyl-2-oxo-3-aza-6,8-
dioxa-bicyclo[3.2.1]octane-7-carboxylic acid hydroxy-
amide (11)
A solution containing 7 (100 mg, 0.28 mmol), hydroxyl-
amine hydrochloride (97 mg, 1.42 mmol) and NEt3
(236 ll, 1.7 mmol) in CHCl3 (500 ll) was stirred for 5
days at room temperature. The resulting suspension
was then filtered and the organic solvents were evaporat-
ed in vacuo. The crude product was purified by column
chromatography, using ethyl acetate as eluent and
affording 11 (21 mg, 21%) as a white solid.
Mp 197–203 C; 1H NMR (DMSO): d 10.74 (br s, 1H),
9.00 (br s, 1H), 7.71–7.17 (m, 9H), 5.92 (s, 1H), 4.69 (s,
2H), 4.49 (s, 2H), 3.39 (d, 1H, J = 12 Hz), 3.07 (d, 1H,
J = 12 Hz); 13C NMR (DMSO): d 165.9 (s), 165.2 (s),
140.1, 139.7, 135.9 (s), 129.3, 128.7, 127.8, 127.4, 127.0
(d), 99.84 (d), 78.84 (d), 77.46 (d), 51.60 (t), 47.41 (t);
MS m/z 354 (M+, 2), 167 (100); Anal. Calcd for
C19H18N2O5 (354.1): C, 64.40; H, 5.12; N, 7.91. Found:
C, 64.12; H, 5.42; N, 7.53.
6.8. (1S,5S,7R)-3-Biphenyl-4-ylmethyl-3-aza-6,8-dioxa-
bicyclo[3.2.1]octane-7-carboxylic acid hydroxyamide (12)
A solution containing 8 (98 mg, 0.29 mmol), hydroxyl-
amine hydrochloride (97 mg, 1.42 mmol) and NEt3
(242 ll, 1.7 mmol) in CHCl3 (500 ll) was stirred for 5
days at room temperature. The resulting suspension
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ed in vacuo. The crude product was purified by column
chromatography, using ethyl acetate as eluent, affording
12 (26 mg, 26%) as a white solid.
Mp 185–189 C; 1H NMR (DMSO): d 10.55 (s, 1H),
8.80 (s, 1H), 7.67–7.34 (m, 9H), 5.56 (s, 1H), 4.52 (s,
1H), 4.46 (s, 1H), 3.56 (s, 2H), 2.75 (pseudo t, 2H,
J = 10 Hz), 2.42 (d, 1H, J = 11.4 Hz), 2.18 (d, 1H,
J = 11.6 Hz); 13C NMR (DMSO): d 167.3 (s), 140.3,
137.1 (s), 129.7, 129.3, 129.2, 127.7, 127.0 (d), 100.5
(d), 76.92 (d), 76.73 (d), 60.66 (t), 56.42 (t), 55.28 (t);
ESI MS m/z 341 (M+1); IR (KBr) 3317, 3146,
1683 cm1; Anal. Calcd for C19H20N2O4 (340.1): C,
67.05; H, 5.92; N, 8.23. Found: C, 66.66; H, 5.45; N,
8.61.
6.9. 1-Benzyloxycarbamoyl-piperidine-4-carboxylic acid
ethyl ester (14)
A solution of piperidine-4-carboxylic acid ethyl ester
(13) (300 mg, 1.91 mmol) in dry DCM (5 ml) was added
to a solution of triphosgene (187 mg, 0.63 mmol) in dry
DCM (4 ml) at 0 C and under inert atmosphere. The
resulting solution was allowed to reach room tempera-
ture and stirred for 1 day.
To the reaction mixture were then added O-benzyl-hy-
droxylamine hydrochloride (336 mg, 2.1 mmol) and
NEt3 (850 ll, 6.1 mmol) and the resulting solution was
stirred for 2 h. The reaction mixture was then concen-
trated under reduced pressure, diluted with DCM,
washed with H2O and brine, dried over Na2SO4 and
concentrated in vacuo. The crude product was purified
by column chromatography (Aluminium oxide, ethyl
acetate/petroleum ether 2:1 to clean up impurities; ethyl
acetate to isolate the final product) to afford 14 (238 mg,
40%) as a pale yellow oil.
1H NMR (CDCl3): d 7.54–7.25 (br s, 5H), 7.11 (br s,
1H), 4.84 (s, 2H), 4.14 (q, 2H, J = 7.07 Hz), 3.95–3.78
(m, 2H), 3.02–2.79 (m, 2H), 2.57–2.35 (m, 1H), 1.99–
1.80 (m, 2H), 1.77–1.51 (m, 2H), 1.25 (t, 3H,
J = 7.11 Hz); 13C NMR (CDCl3): d 174.2 (s), 158.8 (s),
135.9 (s), 129.1, 128.5, 128.5 (d), 77.94 (t), 60.61 (t),
43.32 (t), 40.79 (d), 27.70 (t), 14.17 (q); MS m/z 306
(M+, 1), 91 (100); IR (CHCl3) 1724, 1676, 1222 cm
1;
Anal. Calcd for C16H22N2O4 (306.16): C, 62.73; H,
7.24; N, 9.14. Found: C, 61.65; H, 7.74; N, 8.94.
6.10. 1-Hydroxycarbamoyl-piperidine-4-carboxylic acid
ethyl ester (15)
A stirred solution of 14 (150 mg, 0.5 mmol) in AcOEt
was submitted to hydrogenolysis over 10% Pd/C at
1 atm overnight. After separation of the catalyst by cen-
trifugation, the solvent was evaporated and the crude
residue washed with Et2O affording 15 (108 mg, quanti-
tative) as a white solid.
Mp 101–104 C; 1H NMR (CDCl3): d 6.46 (br s, 1H),
4.13 (q, 2H, J = 7.09 Hz), 3.86 (dt, 2H, J1 = 13.45,
J2 = 3.69 Hz), 3.05–2.81 (m, 2H), 2.48 (m, 1H),2.03–1.82 (m, 2H), 1.78–1.53 (m, 2H), 1.24 (t, 3H,
J = 7.16); 13C NMR (CDCl3): d 171.8 (s), 158.2 (s),
58.02 (t), 40.14 (t), 37.91 (d), 24.81 (t), 11.44 (q); ESI
MS m/z 217 (M+1); IR (CHCl3) 3682, 1724, 1668,
1218 cm1; Anal. Calcd for C9H16N2O4 (216.11): C,
49.99; H, 7.46; N, 12.96. Found: C, 49.55; H, 7.45; N,
12.89.
6.11. (1S,5S,7R)-3-Benzyl-3-aza-6,8-dioxa-bicy-
clo[3.2.1]octane-7-carboxylic acid (biphenyl-4-ylmethyl)-
amide (17)
A mixture containing BnBTGOMe (16) (314 mg,
1.19 mmol) and biphenyl-4-yl-methylamine (1 g,
4.6 mmol) was allowed to reach 60 C and was stirred
at the same temperature overnight. Once the reaction
was completed the crude product was purified by col-
umn chromatography using ethyl acetate/petroleum
ether (1:2) as eluent and affording 17 (460 mg, 93%) as
a white solid.
Mp 98–101 C; ½a23D +23.7 (c 0.5, CH2Cl2); 1H NMR
(CDCl3): d 7.58–7.19 (m, 14H), 6.97 (br s, 1H), 5.59 (s,
1H), 4.79 (s, 1H), 4.69 (s, 1H), 4.65–4.37 (m (ABX sys-
tem), 2H), 3.57 (m, 2H), 2.87 (d, 2H, J = 10.6 Hz), 2.55
(d, 1H, J = 11.8 Hz), 2.34 (d, 1H, J = 11 Hz); 13C NMR
(CDCl3): d 171.1 (s), 140.6, 140.4, 136.7 (s), 128.8, 128.7,
128.4, 128.0, 127.4, 127.3, 127.3, 127.0 (d), 101.2 (d),
77.44 (d), 77.38 (d), 61.54 (t), 56.30 (t), 55.02 (t), 42.87
(t); MS m/z 414 (M+, 7), 91 (100); IR (CHCl3) 3418,
1674, 1521, 1106 cm1; Anal. Calcd for C26H26N2O3
(414.19): C, 75.34; H, 6.32; N, 6.76. Found: C, 74.96;
H, 6.25; N, 6.37.
6.12. (1S,5S,7R)-3-Aza-6,8-dioxa-bicyclo[3.2.1]octane-7-
carboxylic acid (biphenyl-4-ylmethyl)-amide (18)
A solution of 17 (438 mg, 1.06 mmol) and ammonium
formate (300 mg, 4.76 mmol) in MeOH (8 ml) and over
10% Pd/C was refluxed for 2 h under N2 atmosphere.
After separation of the catalyst by filtration over a
pad of Celite, the solvent was evaporated to afford 18
(220 mg, 64%) as a white solid.
Mp 89–92 C; ½a22D +11.8 (c 1.0, CHCl3); 1H NMR
(CDCl3): d 7.59–7.26 (m, 9H), 6.98 (br s, 1H), 5.57 (s,
1H), 4.79 (s, 1H), 4.68 (s, 1H), 4.52 (m, 2H), 3.29 (d,
1H, J = 13.2 Hz), 2.98 (d, 2H, J = 13.6 Hz), 2.80 (d,
1H, J = 13.6 Hz); 13C NMR (CDCl3): d 171.0 (s),
140.6, 136.7 (s), 128.7, 128.0, 127.4, 127.3, 127.0 (d),
101.1 (d), 77.42 (d), 54.21 (t), 53.84 (t), 42.86 (t); MS
m/z 324 (M+, 5), 167 (100); IR (CHCl3) 3420, 1673,
1527, 1110 cm1; Anal. Calcd for C19H20N2O3
(324.15): C, 70.35; H, 6.21; N, 8.64. Found: C, 70.25;
H, 5.91; N, 8.90.
6.13. (1S,5S,7R)-3-Aza-6,8-dioxa-bicyclo[3.2.1]octane-
3,7-dicarboxylic acid 3-(benzyloxy-amide) 7-[(biphenyl-4-
ylmethyl)-amide] (19)
O-Benzyl-hydroxylamine16 (69 mg, 0.56 mmol) was dis-
solved in anhydrous THF (1.6 ml) and added dropwise
to a cooled solution of carbonyldiimidazole (91 mg,
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After being stirred for 30 min at room temperature,
the resulting solution was added to the neat 18
(181 mg, 0.56 mmol) and the reaction mixture was stir-
red overnight. The solution was then diluted with
AcOEt, washed with water and brine, dried over
Na2SO4 and evaporated in vacuo. Crystallization at
room temperature from ethyl acetate afforded the pure
19 (160 mg, 60%) as a white solid.
Mp 110–114 C; ½a26D +29.6 (c 0.77, CDCl3); 1H NMR
(CDCl3): d 7.60–7.26 (m, 14H), 6.90 (br s, 1H), 5.62 (s,
1H), 4.85 (s, 2H), 4.76 (s, 1H), 4.60–4.48 (m, 3H), 3.89
(d, 1H, J = 12.8 Hz), 3.70 (d, 1H, J = 12.8 Hz), 3.33
(d, 1H, J = 13 Hz), 3.04 (d, 1H, J = 12.8 Hz); 13C
NMR (CDCl3): d 169.9 (s), 159.3 (s), 140.6, 136.4,
135.5 (s), 129.0, 128.7, 128.5, 128.5, 128.0, 127.4,
127.4, 127.0 (d), 99.78 (d), 78.21 (d), 75.69 (d), 47.42
(t), 46.88 (t), 42.98 (t); MS m/z 473 (M+, 2), 324 (12),
167 (100), 91 (61); IR (CDCl3) 3420, 1677, 1527 cm
1;
Anal. Calcd for C27H27N3O5 (473.20): C, 68.48; H,
5.75; N, 8.87. Found: C, 68.38; H, 5.61; N, 8.92.
6.14. (1S,5S,7R)-3-Aza-6,8-dioxa-bicyclo[3.2.1]octane-
3,7-dicarboxylic acid 7-[(biphenyl-4-ylmethyl)-amide]
3-hydroxyamide (20)
A stirred solution of 19 (120 mg, 0.25 mmol) in THF
was submitted to hydrogenolysis over 10% Pd/C at
1 atm, at room temperature, overnight. After separation
of the catalyst by filtration through a pad of Celite, the
solvent was evaporated and the crude residue washed
with Et2O affording 20 (65 mg, 68%) as a white solid.
Mp 75–80 C; ½a26D +36.6 (c 0.75, CDCl3); 1H NMR
(CDCl3): (Mixture of rotamers): d 11.58 (br s, 1H),
8.41 (br s, 1H), 7.62–7.20 (m, 9H), 7.13–6.90 (m, 1H),
5.65 (s, 1H, minor rotamer), 5.60 (s, 1H, major rot-
amer), 4.78 (s, 1H, minor rotamer), 4.73 (s, 1H, major
rotamer), 4.66–4.57 (m, 1H), 4.55–4.38 (m, 2H), 4.02–
3.84 (m, 1H), 3.80–3.62 (m, 1H), 3.41–3.24 (m, 1H),
3.18–2.96 (m, 1H); 13C NMR (CDCl3): (mixture of rota-
mers): d 170.8 (s, major rotamer), 170.5 (s, minor rot-
amer), 161.5 (s, major r.), 159.0 (s, minor r.), 140.6,
140.5, 136.5 (s), 128.8–127.0 (d), 99.79 (d), 77.22 (d, min-
or r.), 76.93 (d, major r.), 75.68 (d), 47.46 (t, minor r.),
46.97 (t, major r.), 46.48 (t, minor r.), 45.88 (t, major
r.), 42.80 (t); MS m/z 383 (M+, 0.2), 324 (7), 167 (100);
IR (CDCl3) 3420, 1668 cm
1; Anal. Calcd for
C20H21N3O5 (383.15): C, 62.65; H, 5.52; N, 10.96.
Found: C, 62.30; H, 5.96; N, 10.40.Acknowledgments
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Abstract: The efficient synthesis of a bicyclic a-amino acid from L-
ascorbic acid is presented. The synthetic procedure is a three-step
process involving an SN2 reaction of an amino acetal with an L-
ascorbic acid derivative, followed by protection of the amine as a
Fmoc urethane, and acid-promoted trans-acetalization to give the ti-
tle compound. Inversion of the configuration at the stereocenter of
the precursor derived from L-ascorbic acid allowed the formation of
the corresponding bicyclic a-amino acid bearing the carboxylic
group in the 2-exo configuration. Such Fmoc-protected a-amino ac-
ids can be considered as bicyclic mimetics of proline, and are par-
ticularly suited for solid-phase peptidomimetic chemistry.
Key words: scaffold, peptidomimetic, amino acids, peptides, pro-
line
During the last years, much interest has been paid to pep-
tidomimetics, both in organic and medicinal chemistry, as
they are much more selective and efficient than native
peptides. Furthermore, they can have fewer side effects
and greater oral bioavailability, as the lowered enzymatic
degradation allows for longer biological activity.1 There-
fore, there is an ever-increasing need for versatile scaf-
folds, including new amino acid templates, to be applied
in peptidomimetic design.2 Among the various approach-
es for mimicking peptide structures,3 numerous mimetics
and analogues of proline have been developed and applied
in the synthesis of biologically active compounds,4 espe-
cially with the aim of modulating the cis/trans isomerism
of acyl–proline bonds, and producing proline-like reverse
turn inducers.5
Since the development of the first examples of 6,8-dioxa-
3-azabicyclo[3.2.1]octane-based scaffolds (BTAa, see
Figure 1), functionalities have been introduced at posi-
tions 3, 4, 5, and 7,6 whereas position 2 has remained
largely unexplored, occupied only by C=O, C=S, or CH2
groups. In particular, the possibility of generating scaf-
folds with differently positioned carboxy groups
(Figure 1, A–C) has been pursued recently, to expand the
scope of peptidomimetic chemistry within this class of bi-
cyclic scaffolds. For this approach, new synthetic strate-
gies have been necessary, using different building blocks
from the chiral pool.7
Recently, we moved from tartaric acid to sugars as build-
ing blocks for new versatile scaffolds in enantiopure form
with complete control of the stereochemistry.7 In particu-
lar, it was possible to generate new enantiopure bicyclic
amino acids, such as g- or d-amino acids as reverse turn
inducers, by use of erythrose derivatives7b and bicyclic
proline mimetics starting from serine and glyceraldehyde
derivatives.7a We reasoned that starting from L-ascorbic
acid derivative 1 (Scheme 1), we could produce a new set
of scaffolds bearing a substituent at position 2 (Figure 1,
D). L-Ascorbic acid has appeared in literature as a valu-
able source of chiral building blocks for the preparation of
enantiopure b-lactams8 and L-hexoses.9 Moreover, the use
of such an inexpensive starting material is an advantage in
multigram-scale organic synthesis.
Figure 1 General formula of BTAa scaffolds (top) and isomeric bi-
cyclic amino acids A–D, with A and D as proline mimetics
Thus, starting from triflate 2, obtained from the protected
L-ascorbic acid derivative 1,8,10 compound 4 was obtained
in 99% yield by nucleophilic substitution with amino-
acetaldehyde dimethyl acetal (3) at room temperature and
after overnight stirring (Scheme 1). Further protection
gave Fmoc urethane 5, which was obtained with 9-fluor-
enylmethyl chloroformate in 1,4-dioxane as solvent,
whereas N-(9-fluorenylmethoxycarbonyloxy)succinim-
ide did not yield any product. Then, Fmoc derivative 5
was subjected to acid cyclization at 0 °C, according to re-
ported procedures,7 to afford the the methyl ester of scaf-
fold 6. Surprisingly, the corresponding carboxylic acid 6
was obtained as the major product by concomitant depro-
tection of the carbomethoxy group, and the conversion to
acid 6 went to completion when the reaction was conduct-
ed at 25 °C. Since the preparation of 4-endo-carboxy scaf-
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folds proved to be problematic and low yielding, as
previously reported (see Figure 1, structure A),7a the facile
synthesis of 6, with the carboxy group in the endo posi-
tion, provides a more complete collection of bicyclic ami-
no acids for application in peptidomimetic chemistry.
Scheme 1 Synthesis of a bicyclic a-amino acid with an endo-car-
boxy group from L-ascorbic acid
Formal inversion of the configuration at the C-2 stereo-
center of compound 1 gives 13, the corresponding diaste-
reomer of 6, carrying the carboxy group in the 2-exo
position (Scheme 2). Thus, treatment of L-ascorbic acid
derivative 1 with chloroacetic acid and triphenylphos-
phine, as previously reported,9 produced the correspond-
ing ester derivative 7 with inversion of configuration at C-
2 (Scheme 2). Subsequent hydrolysis with sodium hydro-
gen carbonate in place of triethylamine gave 8, the stereo-
isomer of 1, which was converted into the corresponding
triflate derivative 9 in 53% yield. The reaction of triflate 9
with acetal 3 gave adduct 10, a diastereomer of 4, with in-
version of configuration at C-2. Successively, Fmoc pro-
tection by the same procedure used to prepare 5 yielded
11, which was subsequently cyclized by treatment with
trifluoroacetic acid. Interestingly, in this case, the reaction
provided the bicyclic scaffold as methyl ester derivative
12 (Scheme 2), since the concomitant hydrolysis failed to
occur, probably because of the axial orientation of the
methoxycarbonyl group. This led to the hypothesis that
the facile hydrolysis to give compound 6 might occur
through the urethane carbonyl group providing anchimer-
ic assistance to the equatorial methoxycarbonyl group.
Compound 12 could be obtained in excellent yield when
the cyclization time was prolonged from 16 hours (35%
yield) to 48 hours (81% yield).
Hydrolysis of 12 (Scheme 2) proved to be problematic,
and different methods were tried. Specifically, basic hy-
drolysis with lithium hydroxide did not yield a-amino
acid 13 in significant amounts, and partial Fmoc-depro-
tection of 12 was observed. Hydrolysis with a dioxane–
water system at room temperature for 48 hours gave 13 in
19% conversion, and a similar result (17%) was achieved
when ester 12 was treated with 4 M aqueous hydrogen
chloride in acetonitrile. However, when ester 12 was re-
fluxed in the same aqueous hydrogen chloride–acetoni-
trile system for 16 hours, acid 13 was obtained in
satisfactory yield (75%) (Scheme 2).
In conclusion, a new bicyclic a-amino acid was synthe-
sized in a three-step procedure starting from an L-ascorbic
acid derivative, producing amino acid derivative 6 direct-
ly after acid cyclization. In addition, inversion of config-
uration at the carbon atom bearing the triflate group of the
L-ascorbic acid derivative allowed the synthesis of the
corresponding diastereomeric bicyclic amino acid 13,
which has the carboxy group in the 2-exo configuration.
These two new bicyclic proline analogues may thus find
application in peptidomimetic research, and, in particular,
are suited for solid-phase organic and peptide synthesis by
the Fmoc protocol.
Scheme 2 Synthesis of a bicyclic a-amino acid with an exo-carboxy
group from L-ascorbic acid
Melting points are uncorrected. Chromatographic separations were
performed on silica gel by flash-column techniques. Rf values were
obtained by TLC carried out on 25-mm silica gel plates (Merck
F254), with the same eluent used for the column chromatography.
1H and 13C NMR spectra were recorded with a Varian Gemini 200
or a Varian MercuryPlus 400 instrument. IR spectra of CH2Cl2 or
CDCl3 solns were recorded on a Perkin-Elmer 881 spectrophotom-
eter. Mass spectra were carried out with a Shimadzu spectrometer
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operating with EI at 70 eV. Microanalyses were carried out with a
Perkin-Elmer 2400/2 elemental analyzer. Optical rotations were de-
termined on a JASCO DIP-370 instrument.
Methyl (R)-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl](trifluorometh-
ylsulfonyloxy)acetate (2)
A soln of 1 (5.00 g, 26.3 mmol) in dry CH2Cl2 (45.5 mL) was cooled
to –10 °C, and precooled dry pyridine (4.50 mL) was added. Then a
soln of Tf2O (7.30 mL, 34.2 mmol) in dry CH2Cl2 (13.6 mL) was
added over 30 min, and the mixture was stirred at r.t. for 30 min. Af-
ter the organic phase had been washed with a sat. NaHCO3 soln (3
× 50 mL), the organic layer was dried (Na2SO4), filtered, and con-
centrated in vacuo to give a dark oil. Flash chromatography (silica
gel, PE–EtOAc, 2:1) afforded 2 as a white solid; yield: 4.98 g
(59%).
Mp 51–54 °C; [a]D25 +38.8 (c 0.8, CH2Cl2); Rf = 0.6 (PE–EtOAc,
2:1).
IR (CDCl3): 3052, 2986, 1733, 1265 cm–1.
1H NMR (400 MHz, CDCl3): d = 5.04 (d, J = 5.5 Hz, 1 H, TfOCH),
4.56–4.52 (m, 1 H, ring H-4), 4.18 (dd, J = 9.4, 6.7 Hz, 1 H, CHH),
4.06 (dd, J = 9.4, 4.7 Hz, 1 H, CHH), 3.88 (s, 3 H, OCH3), 1.45 (s,
3 H, CH3), 1.36 (s, 3 H, CH3).
13C NMR (100 MHz, CDCl3): d = 165.1 (s, C=O), 121.5 (s, CF3),
111.1 [s, C(CH3)2], 82.6 (d, TfOCH), 74.1 (d, ring C-4), 65.4 (t,
CH2), 53.5 (q, OCH3), 25.9 (q, CH3), 25.0 (q, CH3).
MS (EI, 70 eV): m/z (%) = 322 (8) [M+], 69 (100), 55 (77).
Anal. Calcd for C9H13F3O7S: C, 33.54; H, 4.07. Found: C, 33.46; H,
3.99.
Methyl (S)-[(2,2-Dimethoxyethyl)amino][(R)-2,2-dimethyl-1,3-
dioxolan-4-yl]acetate (4)
A soln of 2 (1.30 g, 4.01 mmol) in dry CH2Cl2 (20 mL) was cooled
to 0 °C under N2, and then a soln of 3 (0.50 mL, 4.81 mmol) and DI-
PEA (1.40 mL, 8.02 mmol) in dry CH2Cl2 (20 mL) was added. The
mixture was stirred at r.t. for 15 h, and then it was extracted with a
sat. NaHCO3 soln (3 × 40 mL). The organic layer was dried
(Na2SO4), filtered, and concentrated in vacuo to give a dark oil.
Flash chromatography (silica gel, PE–EtOAc, 3:1) afforded pure 4
as a yellow oil; yield: 1.11 g (99%).
[a]D25 +15.6 (c 0.9, CH2Cl2); Rf = 0.47 (PE–EtOAc, 3:1).
IR (CDCl3): 2991, 2955, 2836, 1733, 1250, 1219 cm–1.
1H NMR (400 MHz, CDCl3): d = 4.41 [t, J = 4.8 Hz, 1 H,
(OCH3)2CHCH2NH)], 4.18–4.13 (m, 1 H, ring H-4), 4.07–4.00 (m,
2 H, ring CH2), 3.76 (s, 3 H, CO2CH3), 3.35 (s, 3 H, OCH3), 3.34 (s,
3 H, OCH3), 3.27 (d, J = 7.3 Hz, 1 H, CHNH), 2.76 (dd, J = 12.1,
6.3 Hz, 1 H, CH2NH), 2.63 (dd, J = 12.1, 4.6 Hz, 1 H, CH2NH), 1.72
(br, 1 H, NH), 1.41 (s, 3 H, CH3), 1.31 (s, 3 H, CH3).
13C NMR (100 MHz, CDCl3): d = 173.3 (s, C=O), 109.7 (s), 103.5
[d, CH(OMe)2], 76.8 [d, CHOC(CH3)2], 67.1 (t, CH2NH), 64.4 (d,
CHCO2Me), 53.9 (q, OCH3), 53.2 (q, OCH3), 51.9 (q, OCH3), 49.5
(t, ring CH2), 26.7 (q, CH3), 25.3 (q, CH3).
MS (EI, 70 eV): m/z (%) = 277 (4) [M+], 177 (79), 144 (100), 75
(96).
Anal. Calcd for C12H23NO6: C, 51.97; H, 8.36; N, 5.05. Found: C,
51.84; H, 8.40; N, 5.12.
Methyl (S)-[(2,2-Dimethoxyethyl)(9H-fluoren-9-ylmethoxycar-
bonyl)amino][(R)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate (5)
To a soln of 4 (616 mg, 2.22 mmol) in dioxane (44 mL), at 0 °C and
under N2 were added FmocCl (863 mg, 3.33 mmol) and 2,6-lutidine
(388 mL, 3.33 mmol). The mixture was stirred at r.t. for 15 h. The
soln was then concentrated in vacuo, the crude was dissolved in
CH2Cl2 (20 mL), and the soln was washed with 5% citric acid soln
(3 × 20 mL). The organic layer was dried (Na2SO4), filtered, and
concentrated in vacuo to give 5 as a clear oil. Flash chromatography
(silica gel, PE–EtOAc, 5:1) afforded 5 as a colorless oil; yield: 1.07
g (97%).
[a]D25 –48.1 (c 1.45, CH2Cl2); Rf = 0.1 (PE–EtOAc, 5:1).
IR (CDCl3): 2958, 1794, 1709 cm–1.
1H NMR (400 MHz, CDCl3): d = 7.68 (d, J = 5.4 Hz, 2 H, Ar), 7.51
(d, J = 3.9 Hz, 2 H, Ar), 7.33–7.22 (m, 4 H, Ar), 4.61 (m, 2 H), 3.62
(s, 3 H, OCH3), 4.56–3.02 (m, 14 H), 1.28 (s, 3 H, CH3), 1.25 (s, 3
H, CH3).
13C NMR (100 MHz, CDCl3) (mixture of rotamers): d = 169.7 (s),
156.1 and 155.9 (s), 143.5 (s, 2 C), 141.4 and 141.3 (s, 2 C), 127.7
(d, 2 C), 127.1 (d, 2 C), 124.8 and 124.5 (d, 2 C), 120.1 and 119.9
(d, 2 C), 110.1 and 109.9 (s), 103.4 and 102.9 (d), 74.9 and 74.6 (d),
67.2 and 66.6 (d), 66.1 (q), 62.2 and 61.9 (d), 55.3 and 55.1 (t), 54.4
and 54.1 (t), 52.2 (q, 2 C), 49.6 (d), 47.4 and 47.1 (t), 26.8 and 25.4
(q), 26.6 and 25.4 (q).
MS (EI, 70 eV): m/z (%) = 499 (0.3) [M+], 178 (99), 75 (100).
Anal. Calcd for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C,
64.91; H, 6.62; N, 2.75.
(1R,2S,5S)-3-(9-Fluorenylmethoxycarbonyl)-6,8-dioxa-3-azabi-
cyclo[3.2.1]octane-2-endo-carboxylic Acid (6)
Compound 5 (1.02 g, 2.00 mmol) was dissolved in TFA (4.20 mL),
and the soln was stirred at 25 °C overnight. The soln was then con-
centrated in vacuo to give a dark oil. Flash chromatography (silica
gel, CH2Cl2–MeOH, 20:1, buffered with 0.1% TFA) afforded 6 as a
white solid; yield: 0.351 g (46%).
Mp = 198–201 °C; [a]D25 –78.1 (c 1.0, CH2Cl2–1% TFA); Rf = 0.3
(CH2Cl2–MeOH, 20:1, buffered with 0.1% TFA).
IR (CDCl3): 3691, 2958, 1794, 1602 cm–1.
1H NMR (400 MHz, CDCl3) (2:1 mixture of rotamers): d = 7.69 (d,
J = 7.1 Hz, 2 H, Ar), 7.50 (d, J = 7.8 Hz, 2 H, Ar), 7.33–7.22 (m, 4
H, Ar), 5.16 (s, 2/3 H, H-5, rot. A), 5.11 (d, J = 2.7 Hz, 1/3 H, H-5,
rot. B), 4.68–4.21 (m, 7 H), 3.95 (d, J = 13.4 Hz, 1/3 H, H-4, rot. B),
3.85 (d, J = 13.6 Hz, 2/3 H, H-4, rot. A), 3.06 (d, J = 13.6 Hz, 2/3
H, H-4, rot. A), 2.99 (d, J = 13.4 Hz, 1/3 H, H-4, rot. B).
13C NMR (100 MHz, CDCl3) (mixture of rotamers): d = 173.0 (s,
O–C=O), 158.6 (s, N–C=O), 143.2 (s, 2 C, Ar), 141.0 (s, 2 C, Ar),
127.9 (d, 2 C, Ar), 127.4 and 127.3 (d, 2 C, Ar), 124.9 (d, 2 C, Ar),
120.1 and 119.8 (d, 2 C, Ar), 88.7 and 88.6 (d, C-5), 72.2 and 71.2
(t, C-7), 70.9 and 69.8 (t), 65.4 and 65.0 (d, C-1), 53.9 and 53.8 (d,
C-2), 47.0 and 46.7 (d), 44.4 and 43.7 (t, C-4).
MS (EI, 70 eV): m/z (%) = 381 (1.3) [M+], 178 (100).
Anal. Calcd for C21H19NO6: C, 66.13; H, 5.02; N, 3.67. Found: C,
65.94; H, 4.94; N, 3.55.
Methyl (S)-[(S)-2,2-Dimethyl-1,3-dioxolan-4-yl](trifluorometh-
ylsulfonyloxy)acetate (9)
A soln of 8 (150 mg, 0.79 mmol) in dry CH2Cl2 (1.4 mL) was cooled
to –10 °C, precooled dry pyridine (135 mL) was added, followed by
the addition of a soln of Tf2O (219 mL, 1.02 mmol) in dry CH2Cl2
(0.40 mL) over 30 min. The mixture was stirred at r.t. for 30 min and
then neutralized with a sat. NaHCO3 soln. The organic layer was
separated, dried (Na2SO4), filtered, and concentrated in vacuo to
give a dark oil. Flash chromatography (silica gel, PE–EtOAc, 2:1)
afforded 9 as a yellow oil; yield: 136 mg (53%).
Rf = 0.6 (PE–EtOAc, 2:1).
1H NMR (200 MHz, CDCl3): d = 5.24 (d, J = 3.6 Hz, 1 H, TfOCH),
4.58–4.50 (m, 1 H, ring H-4), 4.10–3.94 (m, 2 H, ring CH2), 3.84 (s,
3 H, OCH3), 1.43 (s, 3 H, CH3), 1.34 (s, 3 H, CH3).
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13C NMR (50 MHz, CDCl3): d = 165.0 (s, C=O), 121.5 (s, CF3),
110.9 [s, C(CH3)2], 81.0 (d, TfOCH), 74.0 (d, ring H-4), 65.4 (t,
CH2), 53.5 (q, O CH3), 25.8 (q, OCH3), 24.9 (q, CH3).
MS (EI, 70 eV): m/z (%) = 322 (3) [M+], 75 (100), 55 (62).
Methyl (R)-[(2,2-Dimethoxyethyl)amino][(R)-2,2-dimethyl-1,3-
dioxolan-4-yl]acetate (10)
A soln of 9 (136 mg, 0.42 mmol) in dry CH2Cl2 (2.1 mL) was cooled
to 0 °C under N2, and then a soln of 3 (56 mL, 0.51 mmol) and
DIPEA (144 mL, 0.84 mmol) in dry CH2Cl2 (2.1 mL) was added.
The mixture was stirred under N2 at r.t. overnight, and then neutral-
ized with a soln of NaHCO3. The organic layer was separated, dried
(Na2SO4), filtered, and concentrated in vacuo to give a dark oil.
Flash chromatography (silica gel, PE–EtOAc, 3:1) afforded pure 10
as a colorless oil; yield: 101 mg (86%).
[a]D25 +19.3 (c 0.7, CH2Cl2); Rf = 0.47 (PE–EtOAc, 3:1).
IR (CH2Cl2): 2990, 2954, 2834, 1739, 1271, 1261 cm–1.
1H NMR (200 MHz, CDCl3): d = 4.41 [t, J = 5.4 Hz, 1 H,
(CH3O)2CHCH2NH], 4.26 (q, J = 6.5 Hz, 1 H, ring H-4), 4.01–3.86
(m, 2 H, ring CH2), 3.71 (s, 3 H, OCH3 ester), 3.31 (s, 7 H, OCH3,
CHNH), 2.80 (dd, J = 12.1, 5.9 Hz, 1 H, CH2NH), 2.57 (dd,
J = 12.4, 5.1 Hz, 1 H, CH2NH), 1.36 (s, 3 H, CH3), 1.29 (s, 3 H,
CH3).
13C NMR (50 MHz, CDCl3): d = 172.7 (s, C=O), 109.6 (s, Cquat),
103.9 [d, CH(OCH3)2], 76.2 [d, CHOC(CH3)2], 66.4 (t, CH2NH),
62.9 (d, CHCO2Me), 54.0 (q, OCH3), 53.2 (q, OCH3), 52.1 (q,
OCH3), 49.5 (t, ring CH2), 26.5 (q, CH3), 25.4 (q, CH3).
MS (EI, 70 eV): m/z (%) = 277 (6) [M+], 177 (75), 144 (89), 75
(100).
Anal. Calcd for C12H23NO6: C, 51.97; H, 8.36; N, 5.05. Found: C,
52.10; H, 8.55; N, 5.14.
Methyl (R)-[(2,2-Dimethoxyethyl)(9H-fluoren-9-ylmethoxycar-
bonyl)amino][(R)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate (11)
To soln of 10 (80 mg, 0.29 mmol) in dioxane (5.8 mL), at 0 °C and
under N2, was added FmocCl (112 mg, 0.43 mmol) and 2,6-lutidine
(50 mL, 0.43 mmol). The mixture was stirred at r.t. under N2 for 15
h. The solvent was concentrated in vacuo, then the crude was dis-
solved in CH2Cl2, and the soln was washed with 5% citric acid soln
(3 × 10 mL). The organic layer was dried (Na2SO4), filtered, and
concentrated in vacuo to give a clear oil. Flash chromatography (sil-
ica gel, PE–EtOAc, 5:1) afforded 11 as a colorless oil; yield: 115 g
(80%).
[a]D25 +48.4 (c 0.95, CH2Cl2); Rf = 0.1 (PE–EtOAc, 5:1).
IR (CH2Cl2): 2988, 1739, 1701, 1261, 1066 cm–1.
1H NMR (200 MHz, CDCl3) (mixture of rotamers): d = 7.81–7.74
(m, 2 H, Ar), 7.63–7.53 (m, 2 H, Ar), 7.44–7.31 (m, 4 H, Ar), 4.77–
3.55 (m, 10 H), 3.68 (s, 3 H, OCH3), 3.37 and 3.32 (s, 6 H, OCH3),
1.41 (s, 3 H, CH3), 1.36 (s, 3 H, CH3).
13C NMR (50 MHz, CDCl3) (mixture of rotamers): d = 169.4 and
168.7 (s), 155.5 and 155.3 (s), 143.7 and 143.6 (s, 2 C), 141.6 and
141.3 (s, 2 C), 127.6 and 127.0 (d, 2 C), 124.8 (d, 2 C), 124.3 and
124.1 (d, 2 C), 120.1 and 119.9 (d, 2 C), 108.9 and 108.6 (s), 104.4
and 104.3 (d), 73.6 and 73.5 (d), 68.6 and 68.5 (d), 67.1 (q), 65.0
and 64.5 (d), 55.8 and 55.6 (t), 55.5 and 55.4 (t), 52.3 and 51.9 (q),
51.8 and 51.3 (q), 47.4 and 47.1 (t), 26.8 and 26.7 (q), 25.2 and 25.1
(q).
MS (EI, 70 eV): m/z (%) = 499 (0.3) [M+], 178 (100), 75 (60).
Anal. Calcd for C27H33NO8: C, 64.92; H, 6.66; N, 2.80. Found: C,
64.90; H, 6.51; N, 2.70.
Methyl (1R,2R,5S)-3-(9-Fluorenylmethoxycarbonyl)-6,8-dioxa-
3-azabicyclo[3.2.1]octane-2-exo-carboxylate (12)
Compound 11 (226 mg, 0.45 mmol) was dissolved in TFA (950
mL), and the soln was stirred at 25 °C for 48 h. Then the soln was
concentrated in vacuo; this gave a dark oil, which was purified by
flash chromatography (silica gel, CH2Cl2–MeOH, 20:1, buffered
with 0.1% TFA) to give pure 12 as a white solid; yield: 145 mg
(81%).
Mp 56–59 °C; [a]D25 +48.5 (c 0.35, CH2Cl2); Rf = 0.8 (CH2Cl2–
MeOH, 20:1, buffered with 0.1% TFA).
IR (CH2Cl2): 2927, 1752, 1708, 1269 cm–1.
1H NMR (400 MHz, CDCl3) (3:2 mixture of rotamers): d = 7.69 (m,
2 H, Ar), 7.51 and 7.41 (m, 2 H, Ar), 7.36–7.21 (m, 4 H, Ar), 5.45
(s, 1 H, H-5), 4.92 (d, J = 3.9 Hz, 3/5 H, H-1, rot. A), 4.78 (d, J = 3.9
Hz, 2/5 H, H-1, rot. B), 4.52–3.64 (m, 7 H), 3.74 and 3.64 (s, 3 H,
OCH3), 3.30 (d, J = 12.5 Hz, 3/5 H, H-4, rot. A), 3.14 (d, J = 13.0
Hz, 2/5 H, H-4, rot. B).
13C NMR (100 MHz, CDCl3) (mixture of rotamers): d = 168.9 (s,
O–C=O), 156.6 (s, N–C=O), 143.5 (s, 2 C, Ar), 141.2 (s, 2 C, Ar),
127.7 and 127.0 (d, 2 C, Ar), 124.9 (d, 2 C, Ar), 124.6 and 124.5 (d,
2 C, Ar), 120.0 (d, 2 C, Ar), 98.9 and 98.4 (d, C-5), 72.7 and 72.3
(d, C-1), 68.2 and 67.7 (t), 67.3 (t, C-7), 59.5 and 58.9 (d, C-2), 52.8
(q), 47.5 and 47.2 (t, C-4), 47.3 (d).
MS (EI, 70 eV): m/z (%) = 395 (0.7) [M+], 336 (2), 178 (100), 165
(14), 89 (7), 55(8).
Anal. Calcd for  C22H21NO6: C, 66.83; H, 5.35; N, 3.54. Found: C,
66.34; H, 5.30; N, 3.46.
(1R,2R,5S)-3-(9-Fluorenylmethoxycarbonyl)-6,8-dioxa-3-aza-
bicyclo[3.2.1]octane-2-exo-carboxylic Acid (13)
A soln of 12 (55 mg, 0.14 mmol) in MeCN (2 mL) and 4 M HCl (3
mL) was refluxed for 16 h, and then the solvent was evaporated in
vacuo. The white solid was treated with Et2O (10 mL), and the soln
was filtered and evaporated. This gave a yellow solid, which was
purified by flash chromatography (silica gel, CH2Cl2–MeOH, 20:1,
buffered with 0.1% TFA), to give 13 as a white solid; yield: 40 mg
(75%).
Mp 86–88 °C; [a]D25 +62.9 (c 0.5, CH2Cl2); Rf = 0.2 (CH2Cl2–
MeOH, 20:1, buffered with 0.1% TFA).
IR (CDCl3): 3066, 2960, 2900, 1709, 1451, 1413 cm–1.
1H NMR (200 MHz, CDCl3) (3:2 mixture of rotamers): d = 10.34
(br, 1 H, COOH), 7.75 (m, 2 H, Ar), 7.60–7.27 (m, 6 H, Ar), 5.55
and 5.53 (s, 1 H, H-5), 5.04 (d, J = 4.6 Hz, 3/5 H, H-1, rot. A), 4.86
(m, 2/5 H, H-1, rot. B), 4.66–3.67 (m, 7 H), 3.36 (d, J = 12.8 Hz, 3/
5 H, H-4, rot. A), 3.19 (d, J = 13.0 Hz, 2/5 H, H-4, rot. B).
13C NMR (50 MHz, CDCl3) (mixture of rotamers): d = 173.5 and
173.3 (s, O–C=O), 156.5 and 155.4 (s, N–C=O), 143.2 (s, 2 C, Ar),
140.9 (s, 2 C, Ar), 128.4 (d, 2 C, Ar), 127.5 (d, 2 C, Ar), 124.7 and
124.3 (d, 2 C, Ar), 119.7 (d, 2 C, Ar), 98.6 and 98.0 (d, C-5), 72.3
and 71.8 (d, C-1), 67.9 (t), 67.3 and 66.9 (t, C-7), 58.7 and 58.4 (d,
C-2), 47.1 and 46.7 (t, C-4), 46.8 (d).
MS (EI, 70 eV): m/z (%) = 381 (0.3) [M+], 178 (100).
Anal. Calcd for C21H19NO6: C, 66.13; H, 5.02; N, 3.67. Found: C,
66.05; H, 4.92; N, 3.65.
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